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Abstract 
Excess deaths from cardiovascular disease are a major contributor to the significant 
reduction in life expectancy experienced by people with schizophrenia. Important risk factors 
in this are smoking, alcohol misuse, excessive weight gain and diabetes. Weight gain also 
reinforces service users’ negative views of themselves and is a factor in poor adherence with 
treatment. Monitoring of relevant physical health risk factors is frequently inadequate, as is 
provision of interventions to modify these. 
These guidelines review issues surrounding monitoring of physical health risk factors and 
make recommendations about an appropriate approach. Overweight and obesity, partly 
driven by antipsychotic drug treatment, are important factors contributing to the development 
of diabetes and cardiovascular disease in people with schizophrenia. There have been 
clinical trials of many interventions for people experiencing weight gain when taking 
antipsychotic medications but there is a lack of clear consensus regarding which may be 
appropriate in usual clinical practice. These guidelines review these trials and make 
recommendations regarding appropriate interventions. Interventions for smoking and alcohol 
misuse are reviewed, but more briefly as these are similar to those recommended for the 
general population. The management of impaired fasting glycaemia and impaired glucose 
tolerance (“pre-diabetes”), diabetes and other cardiovascular risks, such as dyslipidaemia, 
are also reviewed with respect to other currently available guidelines. 
These guidelines were compiled following a consensus meeting of experts involved in 
various aspects of these problems. They reviewed key areas of evidence and their clinical 
implications. Wider issues relating to primary care/secondary care interfaces are discussed 
but cannot be resolved within guidelines such as these. 
 
Keywords 
Alcohol misuse, antipsychotic, aripiprazole, cardiovascular disease, diabetes, dyslipidaemia, 
guidelines, interventions for weight gain, lifestyle, metformin, obesity, overweight, psychosis, 
risk assessment, schizophrenia, smoking cessation, switching 
 
 
INTRODUCTION 
During the last 20 years there has been an increased focus on the problem of premature 
mortality among people with schizophrenia. In part this has been driven by concerns about 
weight gain, concerns that have increased following the introduction of newer antipsychotic 
medications. Local and national audit programmes have highlighted the poor quality of 
monitoring and management of potential physical health problems in people with all types of 
mental health disorder but particularly for those with psychotic illnesses. This has culminated 
in an increased drive not only to achieve greater equality in healthcare resource distribution 
for those with mental health problems, compared to those with physical health problems, but 
also to ensure that those with mental health problems receive proper care for their physical 
health problems (Royal College of Psychiatrists, 2010 and 2013). 
These aspirations have been partially recognised by the UK National Health Service (NHS) 
in its document ‘No Health Without Mental Health: A Cross-Government Mental Health 
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Outcomes Strategy for People of All Ages’ (Department of Health, 2011; paragraphs 3.26 to 
3.30) and through the institution of a specific set of standards for the annual assessment of 
the quality of physical health care provided by Mental Health Trusts to people with 
psychosis, delivered through the national Commissioning for Quality and Innovation 
(CQUIN) programme (NHS England, 2015; indicators 4a and 4b). However, considerable 
progress and commitment will be required to make a significant impact on patient outcomes. 
It is thus important that clinical staff have access to appropriate evidence based 
recommendations regarding how best to monitor and manage physical health problems, and 
particularly risk factors for cardiovascular and metabolic disorders, in people with mental 
illnesses. 
A previous review in the Journal of Psychopharmacology (Barnett et al., 2007) reported the 
conclusions of a pharmaceutical industry funded consensus meeting examining metabolic 
and cardiovascular risk in schizophrenia. That review examined relevant risk factors in some 
detail and the effects of antipsychotic medications. Recommendations were made regarding 
assessment and monitoring of these risks. However, review of potential strategies for 
intervention was limited, in large part because of the lack of available clinical trial and meta-
analysis data at that time. 
The guidelines presented here focus on recent considerations in relation to risk factors for 
cardiovascular and metabolic disorders in people with psychosis, including: assessment of 
risk factors, the evidence of ongoing failure to monitor relevant risk factors adequately and 
then particularly on the evidence relating to suggested strategies for the management of 
weight gain. While interventions for other risk factors (e.g. smoking and alcohol misuse) are 
also important, the evidence regarding these has been reviewed elsewhere but is 
summarised here. Relevant aspects of the current national guidelines regarding 
management of pre-diabetes states, diabetes and other cardiovascular risks, such as 
dyslipidaemia, are discussed. The management of other relevant disorders, such as 
hypertension, should be as within the general population, taking into account any possible 
interactions between antihypertensive, or other, medications and psychotropic medications. 
(Note: The term ‘dyslipidaemia’ is frequently used in this document. Our usage is explained 
in Appendix 1.) 
 
Scope of these guidelines 
The aim of these guidelines is to provide recommendations regarding the monitoring and 
management of risk factors for diabetes and cardiovascular disease, in adults over the age 
of 18 years with psychosis, taking into account the effects of antipsychotic medications and 
with particular emphasis on overweight and diabetes. Most of the evidence reviewed in 
support of these recommendations comes from studies of people with schizophrenia. 
However, a proportion also comes from studies that include people with other forms of 
psychosis, who are receiving treatment with the same antipsychotic medications as those 
with schizophrenia. Thus, it seems reasonable that most of the findings relating to cardio-
metabolic risk and its management can be generalised across the spectrum of common 
psychotic disorders, though they can most reliably be applied to people with schizophrenia. 
We also review relevant key points from current NICE guidelines on the management of 
diabetes and cardiovascular risk. 
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These guidelines are intended to inform psychiatrists, general practitioners, pharmacists, 
nurses, other mental health practitioners and commissioners of services about current 
evidence and to facilitate discussions at local level regarding how best to provide the 
relevant care for people with psychoses. This is an important clinical problem given the 
significant excess mortality from cardiovascular disease suffered by this group. 
At the outset it was decided that we would not attempt to carry out a comprehensive review 
of data relating to children and young people with psychosis. We recognise the problem of 
weight gain in young people, and appropriate interventions for this, as an important topic but 
decided that the paucity of good data relating to this group would make it impossible to write 
similarly evidence based recommendations. Appendix 2 provides a brief discussion of links 
between these guidelines and parallel issues for young people with psychosis. 
It was also decided that it would not be feasible to carry out a similarly evidence based 
review in relation to the monitoring and management of cardio-metabolic risk factors in 
people with intellectual disability, and the possible effects of antipsychotic medications on 
these. Many of the factors involved in people with intellectual disability becoming overweight 
or obese are very different to those in the populations where the randomised controlled trials 
reviewed here have been carried out. The majority of prescribing of antipsychotics in this 
group is not for psychotic disorders. Many studies of interventions for weight gain in this 
population are open studies without a control arm. Again, while this is an important topic, it 
would seem best for it to be addressed by a group with specialist expertise in managing 
people with intellectual disability who would have these guidelines available as a starting 
point. 
As health inequalities for people with a learning disability have been highlighted in a number 
of national reports, attention is drawn to the recommendation by the Royal College of 
General Practitioners (RCGP) that people with an intellectual disability should have an 
annual health check. The RCGP provides a comprehensive and practical guide for this 
(Hoghton et al., 2010). 
 
Summary of Methodology 
A group of nationally recognised experts was invited to an initial meeting on 15th January 
2015. Each was asked to give a brief presentation on a key area relating to the problem with, 
where appropriate, emphasis on randomised controlled trials (RCTs) and meta-analyses. 
Each presentation was followed by a discussion of the important issues in order to identify 
consensus, on the one hand, and areas of uncertainty on the other. A literature review was 
then compiled of evidence for the consensus points. This review and recommendations were 
circulated to the consensus group participants. Their feedback was, as far as possible, 
incorporated into the final version of the guidelines. 
The guideline recommendations are linked to relevant evidence through the literature review. 
However, our methodology and available funding did not allow for a systematic review of all 
possible data from primary sources. Existing systematic reviews and RCTs were identified 
from MEDLINE and EMBASE and from the Cochrane Database. Published NICE guidelines 
on schizophrenia, pre-diabetes, diabetes, lipid modification and substance abuse (CG1, 
CG82, CG115, CG155, CG178, CG181, CG185, CG189, NG28, PH38 and QS80) were also 
considered. 
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Strength of evidence and recommendations for these guidelines 
The categories of evidence applied to the literature reviewed, and the strength of the 
recommendations made, are described in Table 1, which is derived from Shekelle and 
colleagues work on the development of clinical guidelines (Shekelle et al., 1999). ‘Strength 
of Recommendation’ is rated A to D according to category of evidence. A lower rating 
implies a less extensive or robust body of evidence but not necessarily lesser clinical 
importance. The category S represents a standard of care, which describes a consensus 
based on good practice standards rather than evidence. 
Randomised controlled trials must have an appropriate control treatment arm. For primary 
efficacy this should include a placebo condition, although for ‘lifestyle-type’ interventions and 
psychological treatments this may not be feasible. 
 
Table 1: Categories of evidence and strength of recommendations 
Categories of evidence for causal relationships and treatment. 
Ia: evidence from meta-analysis of randomised controlled trials 
Ib: evidence from at least one randomised controlled trial 
IIa: evidence from at least one controlled study without randomisation 
IIb: evidence from at least one other type of quasi-experimental study 
III: evidence from non-experimental descriptive studies, such as comparative studies, 
correlation studies and case-control studies 
IV: evidence from expert committee reports or opinions and/or clinical experience of 
respected authorities 
 
Proposed categories of evidence for observational relationships. 
I: evidence from large representative population samples 
II: evidence from small, well-designed, but not necessarily representative samples 
III: evidence from non-representative surveys, case reports 
IV: evidence from expert committee reports or opinions and/or clinical experience of 
respected authorities 
 
Strength of recommendation. 
A Directly based on category I evidence from meta-analysis of randomised controlled 
trials, at least one large, good quality, randomised controlled trial or replicated, 
smaller, randomised controlled trials 
B Directly based on category II evidence from meta-analysis of randomised controlled 
trials, at least one large, good quality, randomised controlled trial or replicated, 
smaller, randomised controlled trials, or extrapolated# recommendation from category 
I evidence 
C Directly based on category III evidence from non-experimental descriptive studies, 
such as uncontrolled, comparative, correlation and case-control studies, or 
extrapolated recommendation from category I or II evidence 
D Directly based on category IV evidence from expert committee reports or opinions 
and/or clinical experience of respected authorities, or extrapolated# recommendation 
from category I, II or III evidence 
S Standard of good practice 
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#Extrapolation may be necessary because of evidence that is only indirectly related, covers 
only a part or the area of practice under consideration, has methodological problems or is 
contradictory. 
 
 
SUMMARY OF LITERATURE REVIEW AND RECOMMENDATIONS 
It is important to remember that any decisions regarding monitoring of a person’s physical 
health risks, and the decision regarding possible intervention for such risks, should always 
be carried out in collaboration with that individual and, where appropriate, a carer or family 
member. This is perhaps particularly relevant for some of the interventions discussed which 
require significant cooperation from the person involved. 
 
Background 
 Life expectancy is reduced by 20 years in people with schizophrenia. Physical illness, 
and particularly cardiovascular disease, is the main contributor to this (I). 
 A significant proportion of people with schizophrenia develop diabetes and/or have 
other risk factors for cardiovascular disease (especially smoking, overweight/obesity 
and alcohol misuse) (I). These factors are associated with increased cardiovascular 
disease and consequent increased mortality (I). 
 Overweight is an important risk factor for diabetes and cardiovascular disease in 
people with schizophrenia. Factors driving weight gain and the risk of diabetes 
include: poor lifestyle (II), effects of antipsychotic treatment (which varies between 
drugs and which can result in profound weight increase in the first few weeks of 
treatment) (I), pharmacogenetic differences between individuals (II) and direct effects 
of some antipsychotic medications to interfere with insulin secretion (II). 
 Assessment of risk factors for metabolic and cardiovascular disease is vital and 
should be carried out regularly. Evidence from national audit programmes in 
secondary care is that monitoring of such risk factors is inadequately carried out (I). 
 Use of cardiovascular risk prediction models, such as QRISK2, is valuable (I). 
However, QRISK2 has limitations for this population (e.g. only validated for those 
aged over 30 years). In the future, general population prediction models may be 
supplanted by a risk score specifically developed for people with psychosis on 
antipsychotic medications. Current risk scores for the general population may 
underestimate cardiovascular risk for people with psychosis. 
 
Monitoring for physical health risk factors (These are all category S) 
 The measurements below should be assessed before starting an antipsychotic, or as 
soon as possible afterwards, and then at the intervals indicated. 
 Body mass index (BMI) should be used to monitor whether an individual is becoming 
overweight or obese. This requires frequent measurement of weight during the early 
stages of treatment: ideally weekly for the first four to six weeks and then every two 
to four weeks up to 12 weeks, but, as a minimum, once every four weeks for the first 
12 weeks’ of treatment. Weight (and BMI) should then be assessed at 6 months and 
8 
 
at least annually thereafter, unless the clinical situation demands more frequent 
assessment. 
 In the long-term blood glucose control should be monitored using glycated 
haemoglobin (HbA1c). However, as HbA1c provides a measure of longer-term control, 
in the early weeks of treatment, fasting or random plasma glucose may provide a 
more appropriate measure of glucose control. Glucose control should be further 
assessed at 12 weeks, 6 months and then annually. 
 The lipid profile should be assessed at 12 weeks, 6 months and then annually. In 
order to assess cardiovascular risk, for example using the QRISK2 cardiovascular 
risk model, the total cholesterol/HDL cholesterol ratio will be required. A random, 
rather than fasting, sample can be used if a fasting sample cannot be obtained. 
 Blood pressure should be monitored at 12 weeks, 6 months and annually thereafter. 
 If there is a change in antipsychotic medication then, where clinically relevant, it is 
appropriate to re-visit all of the steps outlined above. 
 Tobacco smoking and alcohol use should be enquired about at all opportunities. 
 It is important to take ethnicity into account when evaluating BMI results. 
 
Recommended interventions for overweight and obesity 
Most published RCTs examine the effects of an intervention versus placebo, or other 
appropriate control, to reduce existing weight gain. The majority of the trials of 
pharmacological interventions also include some form of lifestyle approach (usually not 
intensive) for both treatment groups. Some studies in people in their first episode of 
psychotic illness examine attenuation of weight gain versus standard regimens. 
Most clinical trials have been for short or intermediate durations of between 6 and 12 weeks. 
A few have been for 24 weeks or longer. 
Whilst it is not feasible to provide meaningful comparative figures for the mean reduction in 
weight induced by specific strategies, in general most strategies result in weight reduction in 
the range of 2 kg to 3.5 kg and a drop in BMI of around 1 kg/m2. (Note: an increase of 1 
kg/m2 results in an 8.4% increase in risk for development of diabetes.) 
 
 Lifestyle interventions (mostly of the ‘behavioural lifestyle intervention’ type). 
o Lifestyle interventions are recommended as they have a positive effect in the 
majority of RCTs (A). These should almost always be part of the first line of 
approach and in most circumstances should be continued in addition to any 
additional intervention (S). 
o On average, these interventions will reduce existing weight by approximately 
3 kg more, and BMI by approximately 1 kg/m2 more, than the control 
treatment. 
o They will attenuate weight gain in first episode initiations of antipsychotics (B). 
o There is no clear evidence regarding the optimal duration of engagement with 
such interventions. Evidence regarding maintenance of effects is limited in 
both those with long-standing and first episodes of illness. ‘Booster sessions’ 
may be required to maintain effects (C). 
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o A limited amount of evidence suggests that programmes work best if 
designed specifically for those with psychosis and if they combine elements of 
group and individual patient approaches (C). 
 
 Antipsychotic switching. 
o Extrapolation from the evidence, below, suggests that switching to one of the 
antipsychotic medications with lower propensity for weight gain is a strategy 
that should be considered (B). 
o Much of the evidence to support antipsychotic switching strategies inevitably 
comes from meta-analyses of the differential effects of different medications 
on weight. These data suggest a hierarchy of antipsychotic medications with 
respect to weight gain with the following medications appearing to carry the 
lowest propensity for weight gain: haloperidol, ziprasidone, lurasidone, 
aripiprazole, amisulpride and asenapine (asenapine is only licensed for 
bipolar mania in the UK) (A). 
o Only four RCTs have directly examined antipsychotic switching for the 
specific purpose of weight reduction. These supported switching from 
olanzapine to either aripiprazole or quetiapine with an approximately 3 kg 
greater weight reduction with switching compared to no change (B). 
o Clinicians must balance the possible benefit on weight of switching 
antipsychotic medication against the risks of inducing relapse of core 
psychotic symptoms (S). 
 
 Adjunctive aripiprazole. 
o Adjunctive aripiprazole is recommended as a possible intervention for weight 
gain associated with clozapine and olanzapine (B). 
o Three RCTs of the addition of aripiprazole to clozapine or olanzapine, only 
one of significant size, found a mean difference in weight loss for aripiprazole 
over placebo of just over 2 kg (B). 
o Extrapolation of this effect to weight gain induced by other antipsychotic 
medications is not supported by current evidence. 
 
 Adjunctive metformin. 
o In the context of recommendations regarding groups at high risk of diabetes 
in NICE PH38, metformin should be considered as an adjunct to attenuate or 
reduce weight gain following antipsychotic medication (A). It should be 
emphasised that lifestyle interventions should have been fully explored and 
the other interventions, above, considered. 
o Metformin has been compared to lifestyle intervention for weight reduction in 
a large 3-year randomised controlled trial of people at high risk of diabetes in 
the general population. Metformin leads to a modest reduction in weight 
(approximately 2 kg) over the short and long term but is less effective than 
intensive lifestyle intervention (A). 
o Its use in certain situations in people at high risk of diabetes is supported by 
NICE PH38 (S). 
o In people taking antipsychotic medications, short term trials have shown that 
metformin reduces weight, compared to placebo, by approximately 3 kg (A). It 
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attenuates weight gain in first episode initiations of antipsychotic medication 
by approximately 5kg, compared to placebo (A). 
o There are some risks attached to metformin that require appropriate 
monitoring (renal function and vitamin B12) (S). 
 
Other interventions for overweight and obesity 
A wide variety of other treatments have been subject to clinical studies (Table 3). On the 
basis of currently available evidence, those summarised below are not recommended for 
use in routine clinical practice. For some, the evidence either suggests no beneficial effect or 
is currently inadequate to justify their consideration in other than exceptional clinical 
circumstances. For some, the consensus view is that the adverse event profile outweighs 
potential benefits in the majority of clinical circumstances. 
With respect to the treatments described below, the majority of RCTs have been of relatively 
short duration and involved relatively small numbers of participants – around 30-60. 
(A number of other drugs studied in this context have either been withdrawn from use, 
because of safety issues, or are not currently available in the UK. These are not included in 
this summary but are discussed in the main literature review.) 
 
 Orlistat has been subject to RCTs in the general population where it reduces weight 
by approximately 3 kg over one year (A). However, long-term use is extremely limited 
by high rates of discontinuation. In two trials in psychosis an effect was seen only in 
men (B). Clinical experience suggests high-rates of discontinuation in this patient 
group, making it of little value in routine clinical practice (C). 
 Three out of four RCTs of topiramate as an adjunct to antipsychotics reported 
statistically significant weight loss, ranging from 1.5 kg to 5 kg. One RCT supports an 
effect to attenuate weight gain in people with a first episode of psychosis (B). 
However, the risk-benefit profile of topiramate is severely limited by its adverse 
effects (B). 
 Reboxetine has consistent data from three trials suggesting benefit, but all are from a 
single research group with no independent replication yet available (B). 
 Glucagon-like peptide-1 (GLP-1) receptor agonists have been found to be effective 
for weight reduction in obesity in the general population and liraglutide has been 
given marketing authorisation for this use (A). However, there are no RCT data yet 
available for this use in people with psychosis taking antipsychotic medications. 
 Non-RCT data give tentative support to the use of bariatric surgery in extreme 
obesity in a few selected people with schizophrenia. There are no adequate long-
term follow up data available for this population (C). 
 Amantadine, melatonin and zonisamide have all been subject to RCTs that suggest a 
beneficial effect. However, available data are too limited to make any 
recommendation regarding their use. 
 Clinical trials of atomoxetine, dextroamphetamine, famotidine, fluoxetine, fluvoxamine 
and nizatidine have failed to show benefit (B). 
 
Interventions for smoking and alcohol misuse 
 Tobacco smoking. 
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o Tobacco smoking is an important additive risk factor for diabetes and 
cardiovascular disease and those who smoke should be referred to smoking 
cessation services (S). 
o Evidence suggests that all of the treatments below are most effective if 
delivered as part of an overall smoking cessation programme (A). 
o Use of nicotine replacement therapy in smokers with psychosis is supported 
by open-label studies (B). 
o Individual RCTs of buproprion have small numbers of participants, and most 
do not demonstrate statistically significant effects, but meta-analysis of these 
support its use in psychosis (A). 
o Only one of three RCTs of varenicline demonstrates a statistically significant 
effect, but meta-analysis of these RCTs suggests a significant effect (A). 
 
 Alcohol misuse. 
o The negative impact of harmful alcohol use, abuse or dependence in people 
with schizophrenia requires that their alcohol use, as well as use of other 
substances, is assessed and that treatment is appropriately focused on any 
harmful substance use, abuse or dependence (S). 
o Optimisation of antipsychotic treatment, following existing guidance, may have 
a role to play in reducing substance misuse (D). 
o Clozapine should be considered in patients with persisting harmful substance 
use, abuse or dependence, since it has been reported to reduce substance 
use and improve psychosis, but the supporting data are still preliminary (D). 
o Specific medication for relapse prevention in patients with alcohol 
dependence should be considered, such as naltrexone or acamprosate (D). 
 
Management of the increased risks for diabetes and cardiovascular disease 
The management of the medical consequences of weight gain and obesity should be in 
primary care. Initial investigations may be by either the mental health team or the primary 
care team. 
 
 Potential pre-diabetic states should be investigated and managed as per NICE 
guidelines for the general population, except that annual screening for this is 
recommended for those with psychosis receiving antipsychotic medications (S). 
 The prescription of metformin for those not responding to intensive lifestyle 
interventions needs to be considered in the context of the individual (S). 
 Diabetes should be managed by the general practitioner or a specialist physician, 
where necessary, as per existing NICE guidelines (S). 
 Dyslipidaemia, especially in the context of a person with diabetes, should be actively 
managed according to existing NICE guidelines for the general population (S). There 
is no contra-indication to the prescription of a statin in people prescribed 
antipsychotics. 
 Hypertension should be managed according to standard NICE guidelines. 
Practitioners should be aware of possible increased hypotensive effects when some 
antihypertensive medications are combined with antipsychotics (S). 
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Service delivery issues 
 Clinical Commissioning Groups and Trusts, working with clinicians in both primary 
and secondary care, need to ensure that appropriate agreements are in place with 
regard to who takes the lead responsibility for the monitoring and management of 
physical health for people with psychosis at the different stages of their care. 
 This should include sharing of core clinical information between primary and 
secondary care. 
 Primary and secondary care services need to consider how best to provide ‘lifestyle’ 
type interventions within the context of available local provision. 
 
 
The literature reviewed to support these recommendations is described below. 
 
 
BACKGROUND 
The problems 
The life expectancy of people with schizophrenia is reduced by over 20 years (Tiihonen et 
al., 2009). A meta-analysis of 18 international studies indicated that 60% of this excess 
mortality was caused by physical illness (Brown, 1997). Recent large cohort studies in 
Australia and the US have confirmed this increased risk of premature mortality and suggest 
the gap between people with schizophrenia and the general population may be widening 
(Lawrence et al., 2013; Olfson et al., 2015). Excess deaths from cardiovascular disease 
(CVD) are the major contributor to this and people with schizophrenia are twice as likely to 
die from CVD compared to those in the general population (Osborn et al., 2007a; Osborn et 
al., 2015). An increased prevalence of important cardiovascular risk factors is well 
documented in people with schizophrenia (Casey et al., 2004; De Hert et al., 2011). Meta-
analysis suggests that, compared to placebo, most antipsychotic medications are associated 
with weight gain which in turn increases the likelihood of developing a range of physical 
illnesses, including diabetes, cardiovascular disease and cancer. Meta-analysis of 78 
publications, which included 24,892 participants found that 35.3% of people taking 
antipsychotic medications manifest so-called ‘metabolic syndrome’ (Mitchell et al., 2013). 
The literature reviewed in this document sometimes uses the categorical construct of 
‘metabolic syndrome’, most recently described as the combination of central obesity with two 
out of four of hypertension, raised fasting glucose, low HDL cholesterol and raised 
triglyceride levels (Alberti et al., 2005). Use of this terminology has sometimes been useful 
as a way of summarising an important group of risk factors into a single risk factor for the 
development of diabetes and CVD. 
It is important, however, to recognise the individual risk factors for the development of 
diabetes and CVD, as well as making an estimation of overall risk for CVD, and then 
consider provision of appropriate interventions for these individual risk factors. Cigarette 
smoking and misuse of alcohol are important risk factors for CVD in many people with 
psychosis. Overweight is a further important risk factor for CVD and diabetes. It is 
recognised as a common problem among people with schizophrenia (e.g. De Hert at al., 
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2009b). Significant weight gain can be identified within six to eight weeks of commencing 
antipsychotic treatment (Foley and Morley, 2011) and early weight gain appears to be a 
predictor of longer term weight gain (Kinon et al., 2005). A prospective study found that a 
>5% weight gain after one month was the best predictor of long-term weight gain 
(Vandenberghe et al., 2015). In the EUFEST study, of individuals experiencing their first 
episode of schizophrenia, weight gain of ≥ 7% of initial body weight was found in 65% of the 
follow-up population at one year (Kahn et al., 2008). In a study of individuals in the early 
stages of treatment for a first episode of psychosis, Correll et al. (2014) found a pattern of 
increases in several metabolic risk indices after an average of 47 days of antipsychotic 
treatment. 
Weight gain also reinforces service users’ negative views of themselves and may lead to 
poor adherence with treatment (Weiden et al., 2004; Faulkner et al., 2007; Lester et al., 
2011). It is also the most distressing side-effect reported by callers to the SANE helpline 
(Fakhoury et al., 2001).  
Monitoring of patients for the presence of important cardiovascular and metabolic disease 
risk factors, such as smoking, misuse of alcohol, weight gain, elevated plasma glucose, 
dyslipidaemia and hypertension is thus essential. However, it is clear from the results of the 
National Audit of Schizophrenia for England and Wales (Royal College of Psychiatrists, 2012 
and 2014; Crawford et al., 2014; Patel et al., 2014) and from Royal College of Psychiatrists 
Prescribing Observatory for Mental Health (POMH) audits (Barnes et al., 2007; Barnes et al., 
2008) that such monitoring is not routinely carried out and that at best only around one third 
of patients will have adequately comprehensive monitoring of physical health risk factors 
once in any 12-month period. The NAS also demonstrated that the frequency of intervention 
for identified risk factors is poor, e.g. only 52% for elevated body mass index (BMI) and 56% 
for elevated plasma glucose. 
In 2011, the UK national charity Rethink Mental Illness established the independent 
Schizophrenia Commission to collect evidence from a wide variety of sources regarding the 
care of people with schizophrenia. In their report ‘Abandoned Illness’ (Schizophrenia 
Commission, 2012) they also noted the evidence of premature mortality and the need to 
improve delivery of effective physical health care. 
People with psychotic illness and their families are often frustrated because monitoring of 
relevant risk factors and provision of appropriate interventions are sometimes poor, often 
due to lack of clarity within services regarding whose responsibility these should be. Further, 
they want to know about the possible physical health risks at the commencement of 
treatment in order to guide their choices regarding medication and help them understand 
potential preventative strategies. A common complaint is that these issues are often not 
adequately discussed. In the second round of the National Audit of Schizophrenia (Royal 
College of Psychiatrists, 2014), only 39% of people with schizophrenia felt they had been 
given adequately understandable information about their current medication. 
 
Factors driving metabolic and cardiovascular risk in psychosis 
Clinical factors 
De Hert et al. (2009a) report ‘metabolic syndrome’ to be elevated 2-3 times in people with 
schizophrenia above the prevalence in the general population. Obesity and diabetes are 
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also substantially increased in schizophrenia with estimates of relative risk of 1.5-2 and 2 
respectively (De Hert et al., 2009b; Holt and Mitchell, 2015). This is also seen in the UK 
population. A Northern Ireland study of people with schizophrenia showed a high prevalence 
of obesity (40%) and metabolic syndrome (38%) (Yevtushenko et al., 2008). 
These metabolic disturbances are multifactorial in origin (Holt and Mitchell, 2015; Manu et 
al., 2015). Several disease-related factors appear to contribute. Poor self-care appears to be 
associated with a poor diet. People with psychosis consume more saturated fat (Ryan et al., 
2003), more refined sugar (Stokes and Peet, 2004), less fibre (Osborn et al., 2007b) and 
less fruit and vegetables (McCreadie et al., 2003) than the general population. Many people 
with psychotic illness have a rather sedentary lifestyle (Daumit et al., 2005) and take less 
exercise than the general population (Osborne et al, 2007b). The higher prevalence of 
smoking in people with schizophrenia, even in the early stages of the illness (Barnes et al., 
2006), appears to have no protective effect on body weight and has been reported to be 
associated with increased liability to metabolic syndrome (Yevtushenko et al., 2008). 
People with schizophrenia are also disproportionately represented within inner-city areas 
where health inequalities are found to be greatest (World Health Organisation, 2010). 
Deprivation has also been recognised as an important factor in risk for diabetes (Connolly et 
al., 2000) and cardiovascular disease in the general population and is included in the 
QRISK2 algorithm (Hippisley-Cox et al., 2007). People with mental illness are also likely to 
experience inferior medical care compared to the general population (Mitchell et al., 2009). 
Thus, lifestyle and disease factors may contribute to metabolic pathology in people with 
psychosis. One question that then arises is whether there is an inherent metabolic pathology 
in schizophrenia apparent at, or prior to, the onset of psychosis. The answer to this appears 
to be negative. Studies with drug-naïve people with a first episode of schizophrenia found no 
significant differences in a range of metabolic measures, including blood glucose, lipids, 
insulin and measures of fat deposits (Arranz et al., 2004; Zhang et al, 2004). This lack of any 
significant metabolic difference from the healthy population has also been reported for drug-
naive participants in the EUFEST study (Fleischhacker et al., 2013). 
 
Pharmacological and pharmacogenetic factors 
It is clear from the initial meta-analysis of RCT data by Allison et al. (1999) to the recent 
indirect, multiple treatments, meta-analysis from Leucht et al. (2013), that treatment with 
most antipsychotic drugs can lead to significant weight gain, and that antipsychotics vary in 
their liability to induce weight gain. The latter analysis employed data from 212 trials in 
people with schizophrenia, with a mean duration of illness of 12.4 years, and used data from 
the sixth week (or closest time-point to this) of each trial. It distinguishes three essentially 
discrete groups of drugs with respect to weight gain (Table 2). In a meta-analysis of 48 direct 
comparison RCTs, Rummel-Kluge et al. (2010) described three similar clusters and 
observed that the magnitude of changes in glucose and cholesterol fell broadly into the 
same clusters. 
 
Table 2: Rank order of liability for weight gain among oral antipsychotic drugs 
 Risk of weight gain Notes 
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Olanzapine High 1 
Clozapine High 2 
Chlorpromazine High/Medium 3 
Quetiapine Medium 4, 5 
Risperidone Medium 4, 5 
Paliperidone Medium 4, 6 
Asenapine Low 7 
Amisulpride Low 7 
Aripiprazole Low 7 
Lurasidone Low 7, 8 
Ziprasidone Low 7, 8 
Haloperidol Low 8 
 
Adapted from the multi-comparison meta-analysis by Leucht et al., 2013. 
Notes: 1) significantly greater than quetiapine; 2) not significantly greater than the “medium” group due to the 
high reported variance of relative weight gain; 3) not significantly differentiated from either “medium” or “high” 
groups; 4) significantly lower than olanzapine; 5) significantly greater than asenapine; 6) significantly greater than 
amisulpride; 7) not significantly greater than haloperidol; 8) not significantly greater than placebo. 
 
Such meta-analyses are likely to underestimate the effects of the various antipsychotic 
medications as many participants in these RCTs will have been prescribed antipsychotics for 
some time before recruitment to a clinical trial. Treatment of drug-naive people with first-
episode psychosis has been shown to have rapid and profound effects on body weight with 
average increases of 7% to 8% for risperidone and 13% for olanzapine over 3 months 
(Zhang et al., 2004; Templeman et al., 2005). Along with this increase in weight, reflecting 
fat deposition, are seen changes in other cardiovascular risk factors, including elevations in 
total cholesterol and triglycerides (Zhang et al., 2004). The latter study also showed a 
substantial elevation in circulating leptin, an anorexigenic hormone secreted by adipose 
tissue. Such an elevation is expected in people with increasing fat mass, but in this case the 
effect of this hormone in diminishing food intake is lost. This suggests that one mechanism 
for antipsychotic-induced weight gain might be interference with the hormonal control of food 
intake and body weight (Reynolds and Kirk, 2010). 
Strong candidates for the pharmacological mechanisms that might be responsible for this 
weight gain are provided by the known receptor activities of the antipsychotic drugs 
(reviewed by Reynolds and Kirk, 2010). Perhaps the best candidate for the particularly large 
effects of olanzapine and clozapine on body weight is an antagonism, or inverse agonism, at 
the serotonin 2C (5-HT2C) receptor, although antagonism at other candidate receptors, such 
as the histamine H1 receptor, provide alternative or additional mechanisms. Both of these 
receptors are involved in hypothalamic mechanisms controlling food intake and their 
antagonism could disrupt normal hormonal regulation of this system. Other strongly 
implicated receptors include alpha adrenoceptors, other serotonin receptors and inevitably 
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the dopamine D2 receptor (DRD2), at which all antipsychotic drugs act and which has an 
involvement in both hypothalamic mechanisms and in appetite and reward. 
A few antipsychotic drugs appear to have relatively little effect on body weight (Table 2). For 
some, notably aripiprazole and ziprasidone, this may reflect more than just the lack of a 
hyperphagic effect. Animal experiments suggest these drugs have a protective effect against 
olanzapine-induced food intake and weight gain (Snigdha et al., 2008), which reflects the 
increasing clinical use of adjunctive aripiprazole, discussed below. The pharmacological 
mechanism has not been studied, but may relate to partial agonism at certain serotonin 
receptors and/or to aripiprazole's partial agonist action at DRD2 receptors. 
While drugs vary substantially in their effects on body weight and other metabolic factors, 
individual responses also vary profoundly. Some people demonstrate rapid and substantial 
gains in weight on antipsychotic regimens that in others appear to have little or no effect. 
While lifestyle and diet may contribute, it is apparent that genetic factors are important in this 
individual variability of antipsychotic drug-induced weight gain. 
Common functional polymorphisms in many candidate genes implicated in the control of 
body weight and various aspects of energy and lipid metabolism have been investigated for 
association with weight gain in people receiving antipsychotic drug treatment, and with 
metabolic pathology in chronic schizophrenia (reviewed by Reynolds, 2012; Lett et al., 
2012). Perhaps the strongest and most replicated findings are the associations with 
promoter polymorphisms in the 5-HT2C receptor and leptin genes. There are also several 
other possible genetic polymorphisms involving pharmacological targets of antipsychotic 
drugs (e.g. alpha-2A adrenoceptor), in genes involved in the hypothalamic control of food 
intake and body weight (e.g. melanocortin 4 receptor; leptin receptor) and other genes 
emerging from studies of genetic risk factors for obesity and other metabolic disturbances 
(e.g. fat-mass and obesity associated gene [FTO]; methylenetetrahydrofolate reductase 
[MTHFR]). 
Not only are genetic factors important in contributing to antipsychotic-induced weight gain, it 
is also apparent that they influence the rate or extent of weight loss following a pharmaco-
therapeutic intervention. Thus, some of the polymorphisms consistently reported as 
associated with weight gain also affect the extent of weight loss in people who, having 
developed metabolic risk factors following antipsychotic drug treatment, were switched to 
treatment with an antipsychotic with low weight risk (Roffeei et al., 2014). 
These genetic factors associated with drug-induced weight gain and its metabolic 
consequences provide clues as to the underlying mechanisms and in the future may provide 
opportunities for personalized medicine in the predictive assessment of metabolic risk with 
antipsychotic drug treatment. 
 
Antipsychotic medications and diabetes 
One aspect of the metabolic pathology of schizophrenia is a two-fold increase in diabetes. 
The aetiology of this is complex, with genetic, lifestyle and disease-specific treatment factors 
to consider (Holt and Mitchell, 2015). Observational studies have indicated that compared 
with the general population, the risk of diabetes is higher among people receiving 
antipsychotic medication (Vancampfort et al., 2013) and higher in people with schizophrenia 
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who have experienced multiple episodes, compared to first episode and untreated 
individuals (Mitchell et al., 2013). 
Antipsychotics are likely to increase the risk of diabetes through weight gain as this 
increases insulin resistance. However, this does not explain all the excess diabetes risk 
because some individuals receiving antipsychotics develop diabetes without weight gain. 
Changes in glucose regulation have been shown in non-diabetic people with schizophrenia, 
taking antipsychotic medications, independent of adiposity (Newcomer et al., 2002). Insulin 
resistance has been demonstrated in non-obese people taking antipsychotic medications 
(Henderson et al., 2005). The strongest evidence for abnormalities of glucose regulation 
appears to be in people receiving clozapine and olanzapine (Newcomer, 2005) with 
olanzapine also demonstrating greater elevations in glucose levels than other antipsychotics, 
except clozapine, (Rummel-Kluge et al., 2010). Furthermore, weight gain does not explain 
why some individuals develop diabetic ketoacidosis while receiving antipsychotics as this 
implies a marked reduction in insulin secretion. 
Although the underlying pharmacological mechanism has not been studied extensively, the 
interaction of antipsychotics with pancreatic β-cell receptors may interfere with normal insulin 
secretion. For example, a correlational analysis of clinical data suggested that antagonism of 
the muscarinic M3 receptor may be the mechanism of this effect (Silvestre and Prous, 2005), 
while experimental studies of islet cells have drawn the same conclusion (Johnson et al, 
2005). This effect is via M3 receptor mediation of glucose-dependent parasympathetic 
acetylcholine regulation of insulin secretion by pancreatic beta-cells. In addition to these 
pancreatic effects, further in vitro work suggests that various antipsychotics may impair 
insulin-mediated glucose uptake and glycogen synthesis. 
 
Tobacco smoking 
People with schizophrenia have much higher rates of tobacco smoking than the general 
population, something that has been recognised for over 50 years (Hughes et al., 1986; 
Kelly and McCreadie, 2000). Individuals in their first episode of illness are significantly more 
likely to be smokers than a population matched for age and sex (odds ratio=6.04; 95% CI: 
3.03 to 12.02; Myles et al., 2012). There is also evidence in people with schizophrenia that 
nicotine has greater effects on some aspects of cognitive performance (Barr et al., 2008) and 
that there is abnormal regulation of high affinity nicotinic receptors compared to healthy 
people (Breese et al., 2000). 
Smoking is clearly established as an important risk factor for the development of coronary 
heart disease in the general population. Recent data from a primary care population in the 
UK confirm that smokers with severe mental illness acquire a similar level of risk from 
smoking (Osborn et al., 2015). Smoking is also an established risk factor for the 
development of diabetes (Wannamethee et al., 2001; Willi et al., 2007; InterAct Consortium, 
2014). 
 
Misuse of alcohol 
A significant proportion of people with schizophrenia misuse alcohol. A meta-analysis 
reported median current alcohol use disorder rates at 9.4% and median lifetime rates of 
20.6% (Koskinen et al., 2009). This is an additional risk factor for CVD and diabetes. 
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It is clear that heavy use of alcohol increases risk for cardiovascular disease (coronary artery 
disease, stroke and peripheral arterial disease), hypertension, cardiomyopathy (and 
subsequent heart failure) and various cardiac rhythm disturbances (e.g. alcohol can prolong 
the QT interval). Controversy continues regarding whether or not light and moderate drinking 
may be protective for cardiovascular disease for some individuals. While many studies 
suggest this may be the case there is evidence of publication bias and cigarette smoking is a 
possible confounder. A recent study using data from the Health Survey for England found 
beneficial effect of light or moderate consumption on all-cause mortality to be limited largely 
to women ≥ 65 years of age (Knott et al., 2015), suggesting that any ‘cardiovascular’ benefits 
may be outweighed by other alcohol related harms. This conclusion is also supported by the 
recent review of guidelines for the consumption of alcohol by the UK Department of Health 
(2016), in which increased risks for various cancers are highlighted. Low and moderate 
alcohol consumption may increase serum HDL cholesterol but moderate consumption may 
also increase the risk of hypertriglyceridaemia. The potential of an increased calorie intake 
from alcohol increases the risk of overweight and obesity. Heavy drinking and binge drinking 
also increase the risk of diabetes, though low consumption may reduce the risk. (See 
Fernandez-Sola, 2015, for review of these issues.) 
 
Assessment of physical health risk factors 
The first NICE Clinical Guideline on the care of people with schizophrenia (NICE CG1, 2002) 
made rather general reference to issues relating to physical health and did not make very 
specific recommendations regarding the management of cardio-metabolic risk factors. 
Growing concerns about weight gain and the development of diabetes and cardiovascular 
disease were reflected in more detailed guidance in Clinical Guideline 82 (NICE CG82, 
2009), which was an update of NICE CG1. However, the most recent guideline (NICE 
CG178, 2014) provides detailed guidance, particularly in sections 1.1.3, 1.3.6.4, 1.3.6.5 and 
1.5.3. This guidance is also reflected in Quality Statements Six and Seven of the recent 
NICE Quality Standard for Psychosis and Schizophrenia in Adults (NICE QS80, 2015) with 
regard to both monitoring of physical health and provision of advice about diet and physical 
activity. The most recent NICE guideline for bipolar disorder (NICE CG185, 2014) makes 
very similar recommendations regarding the monitoring and management of physical health 
risks for people with that diagnosis. 
In relation to ‘Physical health’, NICE CG178 (2014) recommends an assessment of smoking, 
physical activity, weight, waist circumference, blood pressure, fasting blood glucose, 
glycated haemoglobin (HbA1c) and fasting lipids. These measurements are among those 
commonly proposed as important risk factors for the development of cardiovascular disease 
(CVD) and in part have been driven from the findings of the long running Framingham Heart 
Study (https://www.framinghamheartstudy.org). They also include important risk factors for 
the development of type 2 diabetes. (Note: While assessment of waist circumference has 
some theoretical advantage over BMI the former is often measured incorrectly and loses 
validity above a BMI of 35 kg/m2. Further, the most recent NICE Clinical Guideline on 
Obesity [CG189, 2014] advises use of BMI, with waist circumference as a supplementary 
measure in certain circumstances [paragraphs 1.2.2 and 1.2.3].) Thus, we would suggest 
that the recommendation to measure waist circumference in NICE CG178 should not be 
mandatory and instead would recommend that BMI should be calculated from the weight 
and recorded. It is important to take ethnicity into account when interpreting BMI data – a 
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BMI >23 kg/m2 is considered elevated for those of South Asian ethnicity. Experience from 
the National Audit of Schizophrenia is that BMI is not commonly documented in service 
users’ case records and that documentation of waist circumference is even less frequently 
documented. 
In relation to alcohol use, CG178 (2014) recommends assessment of alcohol consumption 
and discussion of this with the individual (sections 1.3.3.1 and 1.3.6.7) but relates this to 
management of mental state symptomatology rather than physical health issues. We would 
recommend that alcohol consumption should be included in any proper assessment of 
physical health risk factors. 
While it is clearly important to intervene when the results of these assessments are outside 
appropriate limits, a global assessment of the risk of serious physical illness is also 
important. This may be useful, for example, in persuading the person with psychotic illness 
to adopt a change in lifestyle or in the decision whether or not to prescribe a statin. The 
evidence is clear that, for example, prediction of the risk for CVD is much better if multiple 
variables are used for the assessment of the risk. In primary care in the UK it is common 
practice to employ the QRISK2 cardiovascular disease risk calculator (http://www.qrisk.org) 
to estimate the 10-year risk of a cardiovascular disease event, such as stroke, transient 
ischaemic episode, myocardial infarction or angina. In the USA a cardiovascular risk 
prediction model has been developed from the Framingham Heart Study data for use in 
primary care (D’Agostino et al., 2008). QRISK2 has been externally validated and been 
demonstrated to have better discriminative properties than the Framingham model for the 
UK population (Collins and Altman, 2012). 
However, both of the above ‘risk scores’ have been developed using data derived from 
samples of the general population. Osborn and colleagues (Osborn et al., 2015) have made 
the argument that such ‘risk scores’ may not properly reflect the risks faced by those with 
psychotic illness for whom there may be possible links to the illness itself, for whom physical 
inactivity can be a significant feature and for whom the effects of antipsychotic medications 
may play a part. A specific problem with QRISK is that it is validated for people over the age 
of 30 years and thus may not adequately assess risk for younger people early in their illness. 
Using data from the Health Improvement Network, collected as part of their PRIMROSE 
research programme (Prediction and Management of Cardiovascular Risk in People With 
Severe Mental Illnesses; www.ucl.ac.uk\primrose), Osborn et al. (2015) have developed two 
CVD risk prediction models that perform better than existing models in populations with 
severe mental illnesses. These both predict observed risk better than the general population 
models, whether such models are derived from US or UK general populations. 
The simpler of their models employs BMI, rather than blood lipid values, but produces an 
almost identical result without the need for collection of lipid data. The variables employed 
are: gender, age, systolic blood pressure, weight, height, presence of diabetes, smoking 
history, prescription of antidepressants, presence of an alcohol problem, deprivation score, 
specific SMI diagnosis and prescription of first and/or second generation antipsychotic 
medications. Thus, the variables involved are similar to those used for prediction of risk in 
the general population and are similar to those recommended by NICE for people with 
psychosis. However, the additional information, which should be readily available in an 
individual’s case records, appears to add an improved level of discrimination between those 
who will have a CVD event and those who will not. 
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Conventionally, in the UK, a high risk for cardiovascular disease, with implications for 
treatment, was regarded as having a 20% or greater risk of such over the course of 10 
years. It is not yet clear if this is the most appropriate threshold for those with severe mental 
illness. More recent guidelines have proposed that a 10% risk should trigger consideration of 
treatment with statins (NICE CG181, 2014). Further work is essential to determine the 
optimal risk thresholds for people with psychotic illness and to explore the cost effectiveness 
of such thresholds. In the meantime, the use of current risk prediction models remains 
appropriate and it is essential that people with psychosis receive timely screening for their 
risk of CVD and should be offered statins where their risk exceeds 10%. 
 
NICE Guidance and observations of current practice in the UK 
Two national audit programmes have provided data on the extent to which NICE guidelines 
for the management of people with schizophrenia have been followed by Trusts. The 
Prescribing Observatory for Mental Health (POMH) is a national quality improvement 
programme within the Royal College of Psychiatrists’ Centre for Quality Improvement, which 
examines discrete aspects of prescribing practice and in which all mental health Trusts in the 
UK are invited to take part. A POMH audit involving 48 Assertive Outreach clinical teams 
(n=1,966 service users from 21 Trusts) found no evidence that measures of obesity, blood 
pressure, blood glucose control and plasma lipids had been documented during the previous 
twelve months in 67%, 60%, 60% and 68% of patients, respectively. For those cases where 
there was evidence of screening, actual results were only available for between 50-70% of 
individuals, varying across specific measures. In a questionnaire to clinical teams it emerged 
that around one third of staff were uncertain whether responsibility for physical health 
screening lay with the mental health team or the primary care team, less than half were 
confident about interpretation of the results and there was a widespread lack of access to 
simple equipment for the task. Repeat audits, using samples from similar clinical teams, over 
the following six years have demonstrated substantial improvements in practice (Barnes et 
al., 2008; Barnes et al., 2015). 
The National Audit of Schizophrenia (NAS) has reported the results of an audit programme 
in which all Mental Health Trusts in England and Wales are asked to participate (Royal 
College of Psychiatrists, 2012 and 2014; Crawford et al., 2014; Patel et al., 2014). In the 
second round of this audit (Royal College of Psychiatrists, 2014), all eligible mental health 
Trusts participated (n=64) and were asked to make a random selection of 100 people with 
schizophrenia or schizoaffective disorder from among those managed in the community, and 
who had been in contact with services for at least 12 months. Data relating to user 
perceptions of services, prescribing, monitoring of physical health care and psychological 
therapies were collected for 5,608 patients. The results showed that, in the previous 12 
months, only 33% of participants had comprehensive monitoring of the five major 
cardiometabolic health risk factors (smoking, BMI, blood glucose control, blood lipids and 
blood pressure). Similar to the findings in the POMH audits, only 53% had a record of BMI in 
the previous year and 56% a record of blood glucose control. Of equal concern was the fact 
that, where the results of monitoring indicated a need for intervention, there was only 
evidence that this had occurred in 71% of those with elevated BMI, 36% of those with 
hyperglycaemia and 25% of those with elevated blood pressure. 
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Data from the service user questionnaire suggested that there were a significant number of 
cases where some of these risk factors may have been monitored in primary care but that 
staff in the Trusts were unaware of the results. It is clear, however, that despite people with 
persistent psychotic illness having increased risks of cardiometabolic disorders, particularly if 
they are being treated with antipsychotic medications, inadequate attention is paid to 
screening for, and monitoring of, these risks, sharing information between primary and 
secondary care teams and to appropriate intervention. 
 
 
INTERVENTIONS 
The following sections discuss possible interventions for excessive weight gain, smoking and 
alcohol misuse. In the context of evaluating the effectiveness of interventions for weight gain, 
widely accepted thresholds are that weight gain of ≥7% is regarded as clinically significant 
and weight loss of ≥5% of body weight is associated with a decrease in cardiovascular risk 
and mortality. Further, for every 1 kg/m2 increase in BMI in the general population, the risk of 
developing new-onset type 2 diabetes increases by 8.4%. It should also be remembered that 
this is an area of treatment where motivation and engagement is important and that this may 
also determine an individual’s decision to enter a clinical trial. 
The data reviewed come almost exclusively from studies in adult populations, usually over 
the age of 18 years. Thus, particularly in relation to pharmacological interventions, 
appropriate cautions and restrictions must be applied if these are being considered for 
children and young people. 
 
Lifestyle interventions 
The NICE guideline on schizophrenia (NICE CG178, 2014: paragraph 1.1.3) and the NICE 
guideline on obesity (NICE CG189, 2014: paragraph 1.4) both recommend lifestyle 
interventions as the initial approach for people who have become overweight or obese. The 
NICE Public Health guidance on preventing type 2 diabetes (NICE PH38, 2012) also 
recommends this approach as the first line for those in the general population at moderate or 
high risk of developing diabetes. Such lifestyle interventions involve strategies to: increase 
physical activity; improve eating behaviour; improve the quality of a person’s diet; and 
reduce energy intake. An ideal programme should involve all of these. 
Randomised control trials confirm the success of lifestyle interventions as primary treatments 
of obesity in the general population, as noted in a Foresight Programme report to 
Government on obesity (‘Foresight: Tackling obesities – future choices project’, Government 
Office for Science, 2007; https://www.gov.uk/government/publications/reducing-obesity-
future-choices). A systematic review of RCTs of behavioural interventions for obesity, in 
adults, versus (for most studies) usual care or remaining on a waiting list, found 44 studies 
with data suitable for meta-analysis (Dombrowski et al., 2010). Studies that combined dietary 
and physical activity approaches, rather than providing either alone, were more successful 
with a mean difference in weight reduction from the control group of 2.9 kg (95% CI -4.3 to -
1.5 kg) at 12 months. 
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At a population level the North Karelia Project in Finland (Puska et al., 1998), in which 
emphasis was put particularly on influencing the dietary and smoking habits of the 
population, but also physical activity, resulted in a 59% reduction in mortality from coronary 
heart disease in men over a 20-year period. 
An increasing number of studies have demonstrated the effectiveness of lifestyle 
intervention for people receiving antipsychotic medication (Caemmerer et al., 2012; Bruins et 
al., 2014). These interventions are often termed ‘behavioural lifestyle programmes’ as they 
commonly include elements of counselling or cognitive approaches to understanding eating 
behaviours. Most involve group sessions to discuss diet and exercise programmes, but also 
offer individual sessions. However, there are large variations in study design and a paucity of 
studies with long-term (one year or more) follow up. No clinical trial has directly compared 
the effectiveness of different lifestyle intervention programmes. 
Bruins and colleagues (Bruins et al., 2014) identified 25 RCTs suitable for meta-analysis, 
which, combined, included 1,518 people with psychotic disorder (schizophrenia, schizo-
affective disorder and bipolar disorder) treated with antipsychotics. The sample size varied 
from 14 to 291, though only two RCTs had more than 100 participants, and the proportion of 
trial drop-outs varied from 0% to 39%. The various lifestyle interventions were aimed at 
either helping people to lose weight or prevention of weight gain. The outcomes included 
body weight and/or metabolic measurements. In 14 studies the duration of intervention was 
less than 3 months; in seven studies 3-6 months; and in only four studies did the 
interventions last for more than 12 months. The frequency and duration of exercise sessions 
varied from 2 hours per week to 30 minutes daily. Most studies combined physical activity 
and dietary restrictions. Some studies also included one or more of motivational interviewing, 
cognitive behaviour therapy or counselling. 
Data were reported in terms of standard mean differences and the overall effect size of 
lifestyle interventions on weight was −0.63 (95% CI=−0.84 to −0.42; p<0.00001), with effect 
sizes of -0.52 for weight loss interventions and -0.84 for weight gain prevention interventions. 
Comparison of individual trials did not show evidence for the superiority of any specific 
intervention. Individual and group approaches to an exercise intervention were less effective 
alone than a combination of both approaches. The lifestyle interventions also demonstrated 
significant positive effects on waist circumference, triglycerides, fasting glucose and insulin. 
There were no significant effects on blood pressure or cholesterol. 
The meta-analysis of Caemmerer et al. (2012) included 17 RCTs, 15 of which were included 
in the Bruins et al. (2014) analysis, and which combined included 810 people with psychotic 
disorder. This meta-analysis reported data in terms of mean differences and found that 
intervention versus control treatment resulted in an overall mean reduction in weight of -
3.12kg (95% CI -4.03 to -2.21; p<0.0001) and reduction in BMI of -0.94 kg/m2 (95% CI -1.45 
to -0.43; p<0.0003). 
The largest of the studies in the Bruins et al. meta-analysis was the ACHIEVE study (Daumit 
et al., 2013) in which 291 participants were randomised to either a behavioural weight 
management programme (with a mixture of group and individual sessions) or standard 
advice with the option to attend quarterly health classes. The programme ran for 18 months 
and 279 participants were available for assessment at this point. At 18 months the mean 
between group difference in weight was -3.2 kg (95% CI -5.1 kg to -1.2 kg; p=0.002) in 
favour of the intervention group. 37.8% of the participants in the intervention group lost ≥5% 
of their initial weight versus 22.7% of the control group. 
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Two more recently published RCTs of reasonable size are InSHAPE and STRIDE. An initial 
clinical trial of the InSHAPE ‘health coaching’ programme demonstrated effectiveness for 
weight loss (Bartels et al., 2013). The more recent trial was designed to replicate the 
application of this programme in normal clinical settings with a full range of service users 
(Bartels et al., 2014). This trial examined effects on weight and cardio-respiratory fitness in 
210 participants who were randomly allocated to the InSHAPE programme or to fitness club 
membership alone for a 12-month period. At the end of 12 months (n=169 completers) the 
intervention participants achieved significant reduction in overall cardiovascular risk (≥5% 
weight loss or improved walking distance on 6-minute walk test) in 51% of cases versus 38% 
in the control group. Though the mean change in weight for intervention versus control group 
was statistically significantly different it was modest (-2.4 kg vs. +0.3 kg; p=0.029). There 
were no between group differences in calorie consumption or overall dietary balance 
between fat, sweets, fruit and vegetables and no group differences in lipid values. However, 
both groups reduced daily calorie consumption by around 15%. At the end of a 6-month 
period following the end of the intervention there was evidence of maintenance of the 
improvements in cardiovascular risk: by 46% of InSHAPE participants versus 37% of control 
participants. 
The STRIDE study (Green CA et al., 2015) recruited 200 participants whose BMI was ≥27 
kg/m2 and who had been receiving antipsychotics for ≥30 days. The intervention involved 
dietary changes, moderate calorie restriction and moderate physical exercise supported by 
two facilitators. Intervention sessions were for 2 hours per week for the first 6 months, 
followed by maintenance sessions over a 6-month period. The intervention group lost more 
weight than the control group at six months (n=181 completers; mean difference -4.4 kg; 
95% CI -6.96 to -1.78) and also at 12 months (n=170 completers; mean difference -2.6 kg; 
95% CI 5.14 to -0.07). (An omnibus Wald test including time and group gave p=0.004 for the 
significance of difference in weight loss.) BMI was also significantly different at 12 months (-
0.97 kg/m2; 95% CI -1.88 to -0.06; p<0.004). Weight loss of ≥5% of body weight at 12 
months was achieved by 47% of the intervention group. In the intervention group fasting 
glucose decreased from baseline to 12 months by 0.33 mmol/l versus 0.17 mmol/l increase 
in the control group (p<0.02) but there were no significant changes in cholesterol (total, HDL 
and LDL), triglycerides or blood pressure. Weight loss was achieved regardless of which 
antipsychotic medication the participant was taking. While weight loss in the intervention 
group continued at a slower pace in the 6-month maintenance phase of the study, the 
control group began lose weight, rather than gain weight, during this phase such that at 12 
months there was no statistically significant difference in the proportions with weight loss 
≥5%. Rates of attrition did not vary between the initial and follow-up phases of the trial. 
Programmes providing some similar interventions have been organised in the UK. For 
example, a programme in the North-West of England, run from 2000 to 2008, initially 
provided weekly group intervention sessions and reported data from an observed cohort of 
113 people with psychosis (Holt et al., 2010). Sixty-four participants completed follow-up at 
one year and 35 at two years. Weight loss continued over the period of the programme and 
the mean weight loss at two years was 7.2 kg (± 0.6 kg). 
Two RCTs have examined the effects of behavioural lifestyle programmes in people during 
their first episode of psychosis, i.e. at the commencement of antipsychotic treatment. 
Alvarez-Jimenez and colleagues in Santander recruited 61 participants (within 6 weeks of 
starting antipsychotics) to either their early behavioural intervention (EBI) programme, 
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offered for three months, or routine care (Alvarez-Jimenez et al., 2006) and subsequently 
followed up this group at two years (Alvarez-Jimenez et al., 2010). At three months those in 
the EBI group had gained significantly less weight than the routine care group (+4.1 kg vs. 
+6.9 kg; p<0.01) and BMI was less affected by treatment (+1.40 kg/m2 vs. +2.39 kg/m2; 
p=0.01). Significantly fewer of those in the EBI group increased their body weight by ≥7%. At 
six months the difference between the EBI and routine care groups only just reached 
statistical significance but at 24 months the differences were no longer statistically significant 
for weight (EBI +9.98 kg vs. routine care +11.46 kg) or BMI (+3.46 kg/m2 vs. +3.94 kg/m2). 
No metabolic or blood pressure data were reported. 
The Keeping Body in Mind (KBIM) programme in Sydney recruited 28 participants (within 4 
weeks of starting antipsychotics) to either their KBIM programme or standard care for a 12-
week period (Curtis et al., 2015). The KBIM group gained 1.8 kg versus 7.8 kg for the 
standard care group (p<0.001). Only 13% of the KBIM group had weight gain of ≥7% versus 
75% of the standard care group. There were no significant changes in fasting lipids, 
triglycerides, glucose or blood pressure in either group. Daily calorie consumption was only 
assessed in the KBIM group but decreased by 25% from baseline (p<0.001). 
The data from these two studies of intervention early in treatment are promising but the 
numbers of participants included are relatively small and in the Santander study the effects 
were not sustained. A recent UK RCT recruited 105 participants, attending early intervention 
services, to a healthy living intervention (Lovell et al., 2014) but found no significant benefit 
on weight or BMI over 12 months, with 78% of ‘intervention group’ participants completing at 
least 6-8 sessions. However, these patients could have a history of illness of up to three 
years at study entry and their mean age was five years older than the participants in the 
Sydney study, suggesting they are commencing the intervention after a much longer period 
of antipsychotic treatment. 
A further UK programme for young people with psychosis, Supporting Health and Promoting 
Excercise (SHAPE), has been running in the Worcester Health and Care NHS Trust. This 
provides a 12-week programme of dietary advice, lifestyle interventions (including smoking 
cessation and exercise) and gym membership for one year, to people attending their early 
intervention in psychosis team. Preliminary data from the first cohort of 17 participants 
indicate attenuation of weight gain of a similar magnitude to that seen in the studies above 
(Smith et al., 2014). One feature of this programme, commented upon by its service users, is 
that it is designed specifically for them and that this makes it more appealing to attend than a 
generic programme at a Leisure Centre aimed at the general population. This is also a 
feature of most of the programmes reviewed above. 
 
Summary 
Overall the available data suggest that programmes (mainly so-called ‘behavioural lifestyle 
programmes’) aimed at improving diet and increasing physical activity can have a positive 
effect, compared to routine care, to help individuals reduce existing antipsychotic induced 
weight gain or attenuate weight gain in those commencing treatment for their first episode of 
psychosis. Across studies, mean reduction in weight, compared to control treatment, is 
around 3 kg and reduction in BMI, compared to control, is around 1 kg/m2. Attenuation of 
weight gain, compared to control treatment, in people experiencing a first episode of 
psychosis varies widely (2.8 kg to 6 kg) but there are only 3 RCTs. 
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There is no clear evidence regarding the optimum length of engagement with such 
interventions. It is also clear that while there may be some maintenance of the benefits from 
such interventions, the trend is for benefits over routine care to diminish over time. This is 
similar to the findings for similar programmes in the general population (Aronne et al., 2009) 
and argues strongly for the need to make booster sessions available over the long term. 
 
Antipsychotic switching 
While lifestyle interventions are always going to be important, consideration of the potential 
role of the person’s existing antipsychotic medication is also important. Ideally regular 
measurement of weight at initiation of treatment, and thereafter, will provide a baseline and a 
trajectory of weight gain against which the effect of any subsequent change in medication 
can be assessed. In the vast majority of situations, low-dosage or discontinuation of 
antipsychotic treatment is unlikely to be feasible without significant risk of clinical relapse. 
However, for certain dose-related adverse effects (e.g. sedation) a reduction in antipsychotic 
dose may be beneficial, where symptom control allows. For other side effects, such as 
weight gain, there appears to be no clear relationship with antipsychotic dose (Newcomer, 
2005; Simon et al., 2009). Switching to a different antipsychotic medication, that evidence 
suggests may have a lower liability for weight gain, commends itself as an appropriate and 
worthwhile treatment option for consideration. 
Few studies have directly examined the effect of switching antipsychotic medication on 
weight and other metabolic measurements, such as plasma glucose and cholesterol. Thus, 
consideration of the likely benefits of switching antipsychotic medication must be 
approached mainly through consideration of the relative effects of different antipsychotics on 
these measures. The problem with such an approach is that the relative liability of individual 
antipsychotics for weight gain and metabolic side effects (Allison, 1999; Taylor et al., 2012; 
Leucht et al., 2013) is based on RCT data which are limited. First, these problems are not 
always reported in antipsychotic trials. Secondly, reports of side effects in antipsychotic 
RCTs may reflect a range of different assessment measures and criteria (Pope et al., 2010). 
Further, the inter-patient variation for these side effects may be greater than the differences 
in liability between individual drugs. The summary below refers primarily to differences in 
propensity for weight gain as fewer studies have provided comparable data for other 
metabolic variables. 
In an indirect, multiple treatments, meta-analysis of 212 short-term clinical trials, Leucht and 
colleagues (Leucht et al., 2013; summarised in Table 2) suggested that all antipsychotics 
examined induced statistically significantly more weight gain than placebo, except for 
haloperidol, lurasidone and ziprasidone (not currently available in the UK). (The other 
antipsychotics examined were: aripiprazole, amisulpride, asenapine, paliperidone, 
risperidone, quetiapine, sertindole, chlorpromazine, iloperidone, clozapine, zotepine and 
olanzapine. Note that this meta-analysis did not include depot or long acting injectable 
compounds.) As indicated in Table 2, antipsychotics could be divided into three essentially 
separate groups on the basis of their influence on body weight, in which haloperidol, 
ziprasidone, lurasidone, aripiprazole, amisulpride and asenapine had the smallest effect. 
Most of the differences found were in the ranges of standard mean differences suggested as 
‘small’ and ‘medium’ (Cohen, 1988). 
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Direct meta-analysis can only compare those treatments for which direct comparative clinical 
trials exist. Inevitably not all of the many possible direct comparisons have been subject to 
specific clinical trials, hence the value of the indirect meta-analysis approach above. 
Rummel-Kluge and colleagues (Rummel-Kluge et al., 2010) identified 48 RCTs, mainly 
comparing olanzapine or risperidone with another antipsychotic, in which there was usable 
data on weight, glucose or cholesterol, for their meta-analysis of direct treatment 
comparisons. These trials included amisulpride, aripiprazole, clozapine, olanzapine, 
quetiapine, risperidone, sertindole and ziprasidone. The analysis suggested that the 
medications included would fall into the same three clusters identified by the much larger 
indirect meta-analysis summarised in Table 2. The findings for changes in glucose and 
cholesterol fell broadly into these same clusters. 
There are a small number of published clinical trials examining the effect on weight of 
switching from one antipsychotic to another. A Cochrane Systematic Review (Mukundan et 
al., 2010) identified four studies (n=636 participants) with adequate data, in which 
antipsychotic medication was switched specifically to ameliorate weight gain. The conclusion 
was that switching from olanzapine to aripiprazole or quetiapine resulted in weight loss and 
decrease in fasting blood glucose. Only a switch to aripiprazole resulted in an improved lipid 
profile. There were no significant differences in clinical outcomes between switchers and 
those participants not switched. 
The World Federation of Societies of Biological Psychiatry (WFSBP) has published a 
guideline on the long term treatment of schizophrenia and management of antipsychotic 
induced adverse effects (Hasan et al., 2013), which includes the management of weight gain 
and metabolic changes. Their conclusions were similar to those of the Cochrane Review for 
weight and metabolic measurements with regard to switching from olanzapine to aripiprazole 
or quetiapine. They also concluded that switching from olanzapine or risperidone to 
ziprasidone, but not from first generation antipsychotics to risperidone, was beneficial for 
both weight and metabolic measurements (data from an open-label study by Weiden et al., 
2008). 
The WFSBP guideline was able to include the more recent study of Stroup and colleagues 
(Stroup et al., 2011). In this study, people clinically stable on olanzapine, quetiapine or 
risperidone, but who were at increased risk for cardiovascular disease, were randomly 
assigned to remain on their current treatment or switch to aripiprazole. Study assessors, but 
not study participants or their clinicians, were blind to treatment allocation. The results 
showed a significant reduction in non-HDL cholesterol (the primary outcome measure) and 
significant reduction in weight for the aripiprazole group (-3.6 kg vs. -0.7 kg; p<0.0001). 
There were no differences in measures of glucose metabolism and no differences between 
switchers and those not switched in symptom outcomes. 
More recently, a pharmaceutical industry sponsored trial of lurasidone, demonstrated mean 
weight loss (observed cases analysis) of 1.9 kg over six months, with 29.0% showing >7% 
weight loss, when participants were switched to open label lurasidone after six weeks of 
treatment with olanzapine (Stahl et al., 2013). 
 
Summary 
The results of the indirect and direct meta-analyses suggest three clusters of antipsychotic 
medications, with respect to liability for weight gain (Table 2). There is thus some rationale to 
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switch from an antipsychotic with greater propensity for weight gain to one with a lower 
propensity, which in terms of medications available in the UK means to haloperidol, 
lurasidone, aripiprazole, amisulpride or (in bipolar mania) asenapine. The studies included in 
the Cochrane and WFSBP guidelines suggest that switching from olanzapine to aripiprazole 
may be worthwhile with more limited data supporting switches from quetiapine and 
risperidone to aripiprazole, olanzapine to quetiapine and olanzapine to lurasidone. Switches 
to ziprasidone may be worth considering but this is not currently an option in the UK. 
Any decision to switch antipsychotic must take into account any risks of reduced clinical 
efficacy in terms of psychotic symptom control and relapse prevention. It also requires 
discussion with the service user regarding the benefits and risks, including other potential 
adverse effects that may be more common with the alternative medication and the possibility 
that the alternative antipsychotic medication may also cause weight gain in some individuals. 
Hence, though haloperidol is an available option, consideration must be given to the high 
risk of extrapyramidal side effects with this, as well as the disincentive of these to good 
medication adherence, making it an unlikely choice. 
 
Use of adjunctive aripiprazole 
Aripiprazole is a dopamine D2 receptor partial agonist with a different profile of adverse 
effects to other antipsychotic medications. Meta-analysis indicates a relatively small effect to 
increase weight compared to the majority of other antipsychotic medications (Leucht et al., 
2013). In a 26-week RCT of aripiprazole versus olanzapine, in people with schizophrenia 
who had experienced acute relapse on their previous antipsychotic medication (n=317), the 
aripiprazole group had a mean weight loss of 1.37 kg against weight gain of 4.23 kg in the 
olanzapine group (p<0.001) (McQuade et al., 2004). This potential to reduce weight in some 
people when switched from other antipsychotics led to consideration of aripiprazole as an 
adjunct to other treatments that had induced weight gain, particularly clozapine, when 
switching may not be an option due to lack of response to other medications. 
There have been three clinical trials, that have reported data on weight, examining the use of 
adjunctive aripiprazole with clozapine and one examining adjunctive aripiprazole with 
olanzapine. The first of these was an open label study of aripiprazole 15-30 mg daily added 
to clozapine (mean dose 455 mg/day) for 6 weeks in 13 people with chronic schizophrenia 
(Henderson et al., 2006). Eight people completed the trial and two withdrew at week 4. 
There was a significant mean decrease in weight of 2.7 kg (p<0.003) with only one of these 
ten participants showing a small increase in weight (<5%). There were statistically significant 
decreases in fasting total cholesterol and total triglycerides but fasting glucose showed a 
small, but non-significant increase. 
The same group then reported the results of a 10-week placebo controlled, double-blind 
crossover study comparing the effects of 15 mg per day of aripiprazole versus placebo on 
weight, lipids and glucose metabolism in overweight and obese people with schizophrenia 
treated with a stable dose of olanzapine (Henderson et al., 2009). Participants received 
either aripiprazole for 4 weeks, followed by a 2-week treatment adjuvant washout and then 
placebo for 4 weeks or the reverse of this. The order of these two possible regimens was 
randomly assigned. No information was provided regarding any ongoing lifestyle advice. 
Fourteen out of 15 participants completed the full trial. Following 4 weeks of treatment with 
aripiprazole there was a significant decrease in weight compared to placebo treatment (-1.3 
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kg [SD 2.1] vs. +1.0 kg [SD 1.5]; p<0.003) and a parallel decrease in BMI (-0.4 kg/m2 vs. 
+0.3 kg/m2; p<0.004). Total serum cholesterol, HDL cholesterol and LDL cholesterol and 
fasting glucose did not change significantly but there were significant decreases in 
triglycerides (p=0.001) and total VLDL cholesterol (p=0.01). 
Fleischhacker and colleagues (Fleischhacker et al., 2010) carried out a multi-centre, double-
blind RCT of aripiprazole versus placebo added to clozapine in 207 outpatients (n=190 
completers) with schizophrenia who did not have optimal control of symptoms on clozapine 
and had experienced weight gain of at least 2.5 kg on clozapine. The main, 16-week phase 
of the study was double-blind and was followed by a 12-week extension phase on an open 
label basis for eligible participants. No information was provided regarding any ongoing 
lifestyle advice. The mean clozapine dose before randomisation was 384 mg/day in the 
aripiprazole group and 363 mg/day in the placebo group. Aripiprazole doses (and 
‘dummy’/placebo aripiprazole doses) began at 5 mg/day but could be increased after 2 
weeks. At 16 weeks, doses were between 5-15 mg/day: mean 12.0 mg/day in the actual 
aripiprazole group and 11.1 mg/day in the ‘placebo’ aripiprazole group. At the end of week 
16 the aripiprazole group had a greater mean decrease in body weight then the placebo 
group (-2.53 kg vs. -0.38 kg; mean difference -2.15 kg, 95% CI -3.17 to -1.12; p<0.001) and 
a statistically significant difference was maintained in those who completed the open label 
phase at week 28. The weight change was paralleled by reductions in BMI and waist 
circumference. Weight loss of ≥7% was achieved by 21% of the aripiprazole group and 13% 
of the placebo group. Aripiprazole was also associated with a significant decrease in total 
cholesterol (p=0.002) and LDL cholesterol (p=0.003) but no change in triglycerides or fasting 
glucose. There were no statistically significant changes in symptom scores on the PANSS. 
A further double blind placebo-controlled RCT of aripiprazole added to clozapine was carried 
out in 38 participants (n=30 completers) with the primary aim of investigating effects on 
glucose metabolism (Fan et al., 2013). The primary outcome measure was the frequently 
sampled intravenous glucose tolerance test (FSIVGTT), which assesses insulin sensitivity 
and the effectiveness of glucose metabolism. This measure improved significantly in the 
aripiprazole group versus the placebo group along with a reduction in plasma LDL. Lean 
body mass, but not fat mass, was significantly decreased. There was a non-significant 
decrease in weight of -1.5 kg in the aripiprazole group and an increase of +0.3 kg in the 
placebo group. There were no significant differences in PANSS symptom scores. 
A meta-analysis of the data from the three double-blind studies (Mizuno et al., 2014) found a 
mean difference between aripiprazole and placebo of -2.13 kg (95% CI -2.87 to -1.39; 
p<0.00001). The most commonly reported adverse effects of the combination treatment are 
nausea, headache, insomnia, anxiety and restlessness. 
The studies above have not demonstrated significant change in schizophrenia symptom 
scores with the addition of aripiprazole. Muscatello and colleagues reviewed the case 
studies, case series and open-label clinical trials of adjunctive aripiprazole and concluded 
that the data provided some, but not conclusive, support that this might be a useful strategy 
for further symptom improvement in people whose illnesses remained relatively treatment 
unresponsive despite clozapine (Muscatello et al., 2011). In the same publication they 
describe a 24-week double blind RCT of aripiprazole versus placebo in 40 participants 
receiving clozapine (31 completers). The results showed a significant improvement in total 
Scale for Assessment of Positive Symptoms score (p<0.0001). This study did not report data 
on weight. 
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Summary 
The addition of aripiprazole to clozapine or olanzapine appears to be an effective strategy 
likely to result in a mean difference of weight loss of around 2 kg with aripiprazole compared 
to placebo. Data regarding effects on cholesterol, triglycerides and glucose were 
inconsistent across the trials but there was a trend for measures of cholesterol and 
triglycerides to improve. Aripiprazole is unlikely to worsen psychotic symptoms. 
Thus, adjunctive treatment with aripiprazole of people with psychosis on clozapine and 
olanzapine would appear to be a safe and potentially effective option to ameliorate weight 
gain without a detrimental effect on symptoms. There is no useful body of evidence 
regarding augmentation of other antipsychotics with aripiprazole for this purpose. It is also 
important to consider the possible disadvantages of polypharmacy versus the degree of 
benefit obtained. 
The value of an augmentation strategy with an antipsychotic drug with low potential for 
weight gain may not be restricted to aripiprazole. There are reports that ziprasidone has 
some efficacy in this respect (e.g. Wang et al., 2011). The use of added amisulpride or 
lurasidone in ameliorating weight gain with antipsychotic treatment has not been explored. 
 
Use of adjunctive metformin 
Metformin hydrochloride is an oral glucose-lowering drug in the biguanide class. It is the first-
line drug of choice for the treatment of type 2 diabetes in all national and international 
guidelines. Its main actions are to reduce hepatic glucose production and increase insulin 
sensitivity in muscle. In the management of diabetes, it has a neutral effect on body weight 
and reduces total cholesterol, LDL cholesterol and triglycerides. 
As discussed above (Antipsychotic medications and diabetes), it appears that antipsychotic 
medications act to increase the risk of diabetes both through weight gain and independent 
mechanisms, with both of these influencing insulin resistance. The practical use of metformin 
in the management of “pre-diabetes” and in diabetes is discussed later in this guideline 
(Management of the increased risk for diabetes and CVD). Here we review the some of the 
evidence that metformin can reduce mortality, reduce the risk of progression to diabetes, 
and reduce weight in overweight and obese individuals at risk of development of diabetes. 
We then review the clinical trial data relating to the use of metformin in overweight and 
obese people with psychosis. 
First we summarise the results of two large clinical studies of the effects of metformin in the 
general population in the UK and the USA. In the United Kingdom Prospective Diabetes 
Study (UKPDS; n=753, with a median duration of 10.7 years in the trial), the use of 
metformin versus conventional treatment (primarily diet) was associated with reductions in 
all-cause mortality, myocardial infarction and microvascular complications (UKPDS, 1998). 
Though these results have recently been criticised (Boussageon et al., 2016), partly for lack 
of replication, other similar studies have been for shorter durations of follow-up and meta-
analysis of these, together with UKPDS, supports the original conclusion (Holman et al., 
2014). 
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A number of clinical trials have examined its effectiveness for the prevention of diabetes. 
The largest (n=3,150) was undertaken in the USA. This was a multi-centre RCT which 
compared the effects of an intensive lifestyle intervention, metformin and placebo in adults in 
the general population at high risk of diabetes (The Diabetes Prevention Programme [DPP] 
Research Group, 2002). This found that diabetes incidence rates during the 2.8 years of the 
DPP were 4.8 cases per 100 person-years (95% CI 4.1 to 5.7) in the intensive lifestyle 
intervention group (58% risk reduction), 7.8 (6.8 to 8.8) in the metformin group (31% risk 
reduction) and 11.0 (9.8 to 12.3) in the placebo group. This trial was then continued into an 
open label phase into which 88% of the original participants were recruited. During the 10.0-
year (IQR 9.0 to 10.5) follow-up since randomisation to DPP, the original lifestyle group lost, 
then partly regained weight. The modest weight loss with metformin was maintained. 
Diabetes incidence rates in this follow-up study were similar between treatment groups: 5.9 
per 100 person-years (5.1 to 6.8) for lifestyle, 4.9 (4.2 to 5.7) for metformin, and 5.6 (4.8 - 
6.5) for placebo. Diabetes incidence in the 10 years since DPP randomisation was reduced 
by 34% (24 to 42) in the lifestyle group and 18% (7 to 28) in the metformin group compared 
with placebo. The research group’s interpretation of these findings was that: “during follow-
up after DPP, incidences in the former placebo and metformin groups fell to equal those in 
the former lifestyle group, but the cumulative incidence of diabetes remained lowest in the 
lifestyle group. Prevention or delay of diabetes with lifestyle intervention or metformin can 
persist for at least 10 years”. 
Thus, in individuals at risk of developing diabetes, evidence suggests that metformin can 
reduce the risk of progression to diabetes, reduce mortality and reduce weight. Lifestyle 
interventions should be the first line of approach for those at high risk of diabetes. However, 
should these fail, metformin is an option in some clinical situations. This is reflected in 
Recommendation 19 of the NICE Public Health guidance ‘Preventing type 2 diabetes: risk 
identification and interventions for individuals at high risk’ (NICE PH38, 2012). In this 
guidance a fasting plasma glucose of 5.5-6.9 mmol/l or an HbA1c level of 42-47 mmol/mol 
[6.0-6.4%] is regarded as indicating a high risk and use of metformin is suggested for: 
 Adults at high risk whose blood glucose measure (fasting plasma glucose or HbA1c) 
shows they are still progressing towards type 2 diabetes, despite their participation in 
an intensive lifestyle-change programme. 
 Adults at high risk who are unable to participate in lifestyle-change programmes 
because of a disability or for medical reasons. 
(For those at low risk of developing diabetes dietary and lifestyle advice are recommended 
with more specific brief lifestyle programmes for those at moderate risk. See later section.) 
In relation to the effects of metformin on weight loss in the general population, a randomised, 
double-blind, placebo controlled RCT in France (Fontbonne et al., 1996), conducted in 457 
non-diabetic people with a high waist-to-hip ratio (n=324 completers at one year), 
demonstrated weight loss in the metformin compared to the placebo group (respectively -2.0 
kg [95% CI -3.0 to -1.1] vs. -0.8 kg [95% CI -1.6 to +0.1]; p<0.06), but fell just short of being 
statistically significant. Weight loss with metformin in the DPP study was of similar 
magnitude and statistically significantly different from placebo (p<0.001). This benefit was 
directly related to degree of adherence with metformin treatment (DPP Research Group, 
2012). A systematic review of studies in non-diabetic, obese young people age ≤19 years 
identified five RCTs of metformin versus placebo (Park et al., 2009). Meta-analyses of the 
data from these indicated that compared with placebo metformin reduced BMI by 1.42 kg/m2 
(95% CI 0.83 to 2.02). 
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A recent meta-analysis of studies where metformin was added to existing antipsychotic 
medication (most commonly clozapine, olanzapine or risperidone) identified 10 RCTs, of 
which four (three by the same author) were in people in their first episode of illness (Mizuno 
et al., 2014). Five of these studies were carried out in China or Taiwan, three in Venezuela, 
one in Iran and one in the USA, so the results may not be entirely generalizable to all 
populations. Furthermore, a funnel plot of these 10 studies suggested some possibility of 
publication bias for studies with smaller samples. The overall results of these studies 
favoured metformin over placebo with a mean difference of -3.17 kg (95% CI -4.44 to -1.90). 
In three studies there was no statistically significant difference between metformin and 
placebo. For the four trials in people with first episode psychosis the mean difference was -
5.01 kg (95% CI -6.41 to -3.62). 
The largest study (Jarskog et al., 2013) was carried out across 17 sites in the USA and 
recruited 148 (n=116 completers) participants with schizophrenia or schizoaffective disorder 
who had been ill for at least 12 months and had a BMI ≥27 kg/m2. All participants received 
weekly diet and exercise counselling and either metformin or placebo for 16 weeks. The 
mean final daily dose of metformin was 1,887 mg (SD=292), similar to everyday clinical use. 
At week 16 the mean weight change for the metformin group was -3.0 kg (95% CI -4.0 to -
2.0) and that for the placebo group was -1.0 kg (95% CI -2.0 to 0.0), a statistically 
significantly difference (p=0.0065). Thirteen metformin and seven placebo participants 
achieved weight loss of ≥5%. BMI was changed by -1.0 kg/m2 in the metformin group and -
0.3 kg/m2 in the placebo group. There was a statistically significant lowering of triglyceride 
levels and in HbA1c at 16 weeks in the metformin group, but no significant difference 
between groups in total cholesterol, HDL- or LDL-cholesterol, fasting glucose or insulin 
levels. The only adverse effect reported that differed between metformin and placebo was 
diarrhoea. While this study indicates a positive effect of metformin for existing antipsychotic 
related weight gain the effect is fairly modest, i.e. a reduction of only one point in BMI. 
However, weight reduction was continuing up to the end of the 16 weeks and thus a longer 
trial might have revealed a larger improvement. 
The longest study, lasting for 24 weeks, was at a single site in China and included people 
with first episode psychosis. Wu and colleagues recruited 84 (n=76 completers) female 
patients within their first year of commencing antipsychotic treatment (mean duration 6.35 
months) and who also experienced amenorrhoea (Wu et al., 2012). The metformin dose was 
1000 mg per day. No information was given regarding other dietary or exercise programmes. 
The metformin group lost -2.3 kg and the placebo group gained +2.1 kg, with respective 
changes in BMI of -0.93 kg/m2 and +0.85 kg/m2. Insulin resistance decreased in the 
metformin group and significantly more of the metformin group resumed menstruation 
(66.7% vs. 4.8%). There were no differences in adverse effects between the two groups. In 
this Chinese population initial weight and BMI were lower than would be found in a Western 
population (mean BMI at baseline was 22.5 kg/m2) and thus the reduction in BMI with 
metformin represents a 4.1% change. Weight loss in the metformin group appeared to 
continue up to month 5 of the study suggesting that any trial of adjunctive metformin 
treatment needs to be given a reasonable period in which to demonstrate maximum effect. 
A 12-week RCT in 40 antipsychotic medication-naïve patients in China (Wu et al., 2008) 
found that those receiving olanzapine plus metformin gained less weight than those 
receiving olanzapine plus placebo (respectively +1.9 kg [SD 2.72] vs. +6.87 kg [SD 4.23]; 
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p<0.02). However, these patients had a long mean pre-treatment duration of illness of 7.2 
years and were inpatients with more limited access to food. 
Klein and colleagues carried out a 16-week RCT in 39 (n=30 completers) service users aged 
10-17 years who had gained more than 10% of their pre-antipsychotic body weight during 
less than 12 months of treatment with either olanzapine, risperidone or quetiapine (Klein et 
al., 2006). All participants and their families were offered regular dietetic advice. The 
participants on metformin (1700 mg/day) showed little change in weight over the treatment 
period (mean -0.13 kg, SD 2.88) while the placebo group continued to gain weight (mean 
+4.01 kg, SD 6.23). Differences between the mean values were significant at weeks 4, 8, 12 
and 16. There was evidence that metformin treatment had an impact on the development of 
abnormal glucose tolerance. There were no differences in adverse effects between the 
treatment groups. 
While adverse effects in the studies above did not appear to differ between metformin and 
placebo treated participants it is important to remember that metformin can cause the 
serious effect of lactic acidosis, with a rate of around nine cases per 100,000 person years 
(often in the context of renal failure). For this reason, metformin is contraindicated in severe 
renal impairment (eGFR <30 ml/min), hepatic failure and heart failure. The risk may also be 
increased by alcohol consumption. Metformin can also decrease absorption of vitamin B12 
and 7% may develop deficiency of this over four years. The more common adverse effects 
are complaints of nausea, bloating abdominal pain and diarrhoea in around 10-20% of 
patients, effects which often result in patients not being able to tolerate the drug. Thus, it is 
usually initiated at a low dose with gradual increase over two to three weeks. 
 
Summary 
These data would suggest that metformin can reverse existing antipsychotic-induced weight 
gain, with a difference from the effects of placebo treatment of approximately 3 kg. Four 
studies suggest it can help to attenuate weight gain in those commencing antipsychotics for 
the first time, but three of these are in Chinese populations and by the same author. There is 
evidence that metformin may improve abnormal glucose intolerance and some aspects of 
lipid profile. However, there is heterogeneity in the data from the available RCTs and many 
of the studies have included some aspect of lifestyle management. Most of the studies 
involve small numbers of participants and are of short duration. No studies reported data on 
whether transition to diabetes was reduced in metformin versus placebo groups. 
Metformin is not appropriate for people with co-morbid harmful use of alcohol or alcohol 
dependence syndrome as alcohol enhances the hypoglycaemic effect of metformin and 
increases the risk of lactic acidosis. It is necessary to monitor renal function and vitamin B12 
levels in those taking metformin. 
 
Other interventions for overweight and obesity 
A number of other treatments have been considered as possible adjunctive treatments and 
subject to clinical trials for weight reduction in the context of antipsychotic induced weight 
gain. Some of these have been subject to clinical trials for weight gain and obesity in the 
general population but some have only been examined in the context of antipsychotic 
induced weight gain. These various treatments are divided into four groups according to 
33 
 
whether clinical trial evidence exists for their effects within antipsychotic treated populations 
and their availability in the UK (Table 3). 
 
Table 3: Treatments that have been studied, or considered, for reduction of antipsychotic 
related weight gain. (Listed in alphabetical order and not order of importance.) 
Group Evidence of efficacy for reducing 
weight gain and availability in the 
UK. 
Treatments given in alphabetical 
order within each group 
 
A Data available for these treatments 
from RCTs in antipsychotic treated 
patients. 
 
Treatments are available in the UK but 
are not necessarily licensed for the 
treatment of obesity. 
 
 
amantadine 
melatonin 
orlistat 
topiramate 
reboxetine 
zonisamide 
B These treatments have evidence of 
efficacy in the general population but 
no trials in antipsychotic treated 
patients. 
 
The last two drugs are not currently 
available for use in the UK. 
 
 
bariatric surgery 
GLP-1 analogues (liraglutide & 
exenatide) 
 
lorcaserin 
phenteramine/topiramate combination 
C For most of these treatments only a 
single (negative) clinical trial has been 
carried out in antipsychotic treated 
patients. 
 
Treatments are available in the UK but 
are not licensed for the treatment of 
obesity. 
 
 
atomoxetine 
dextroamphetamine 
famotidine 
fluoxetine 
fluvoxamine 
nizatidine 
 
D Had limited or no evidence of 
effectiveness in antipsychotic treated 
patients. 
 
Treatments no longer available in the 
UK. 
d-fenfluramine 
phenylpropanolamine 
rimonabant 
rosiglitazone 
sibutramine 
 
 
The treatments listed in Group A, above, are the only ones (aside from possible use of 
bariatric surgery in more extreme cases) that currently merit significant review and the 
evidence relating to these is summarised below. Less detailed discussion about the 
treatments listed in groups B, C and D. 
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Treatments available in the UK with RCTs in antipsychotic treated patients (Group A) 
Amantadine 
Amantadine is an antiviral agent which has been shown to be effective for extrapyramidal 
adverse effects. Clinical trials for weight gain are based on its ability to modify dopaminergic 
and serotoninergic neurotransmission. Praharaj and colleagues (Praharaj and Sharma, 
2012) identified six studies. Four were open-label trials or case series and only two double-
blind, placebo controlled RCTs were identified that could be subject to meta-analysis. In 
Deberdt et al. (2005) 125 participants were recruited, of whom 111 completed a 16-week 
trial. In Graham et al. (2005) 21 participants were recruited, of whom 18 completed a 12-
week trial. Both trials included participants with bipolar disorder as well as schizophrenia. All 
participants received amantadine or placebo in addition to olanzapine but some participants 
were also on antidepressants or mood stabilisers. Both studies reported small, but 
statistically significant, weight loss in the amantadine group and weight gain in the placebo 
group. Meta-analysis suggested an overall beneficial effect for amantadine with a mean 
difference of -1.85 kg (95% CI -3.31 to -0.39). Only the smaller study reported changes in 
BMI (statistically significant). In the larger trial the difference in weight between the two 
groups was only 1.47 kg. 
Note that amantadine is a weak dopamine agonist and has been reported to induce 
psychotic symptoms as an adverse effect. 
 
Melatonin 
Melatonin is a hormone involved in the entrainment of circadian rhythms. It has been shown 
to block olanzapine induced weight gain and visceral adiposity in laboratory rats (Raskind et 
al, 2007) and a relationship has been described between nocturnal melatonin secretion and 
body weight in schizophrenia (Ferrier et al., 1982). Two double-blind RCTs have examined 
the effect of melatonin versus placebo. Romo-Nava and colleagues (Romo-Nava et al., 
2014) studied 44 participants with either schizophrenia or bipolar disorder for 8 weeks using 
melatonin 5mg daily. The melatonin group showed attenuated weight gain versus placebo 
(1.5 kg vs. 2.2 kg; p=0.04) but effects on body fat mass were only seen in the bipolar patient 
group. Modabbernia and colleagues (2014) studied 48 participants in their first episode of 
psychosis who received either olanzapine plus melatonin 3 mg daily or olanzapine plus 
placebo. Weight gain was less in the melatonin group with a mean difference of 3.2 kg 
(p=0.023). 
 
Orlistat 
Orlistat is an inhibitor of gastric and pancreatic lipase and prevents intestinal fat absorption. 
A meta-analysis of 16 placebo controlled RCTs in the general population (Rucker et al, 
2007), showed that orlistat (120 mg three times daily) reduced weight by 2.9 kg (95% CI 2.5 
to 3.2) after one year and more participants in the orlistat group achieved at least 5% weight 
loss. However, because of the adverse effects of orlistat (principally unpleasant 
steatorrhoea) only 70% of participants on average complete formal trials and long-term 
adherence is <2% at 2 years (Padwal et al., 2007). 
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Two studies in people with schizophrenia have demonstrated some effect on weight but in 
both studies the effect is only seen in male participants. Joffe and colleagues (2008) 
commenced 71 participants (63 completed the study) in a 16-week placebo controlled RCT 
of orlistat in addition to clozapine or olanzapine. Only men demonstrated weight loss (-2.36 
kg vs. +0.62 kg; p=0.011). In what appears to be a separate study the same research group 
(Tchoukhine et al., 2011) entered 44 participants on clozapine or olanzapine into a double-
blind placebo controlled study of orlistat followed by a 16 week open-label phase. Again an 
effect was only seen in men and data from the open phase suggested that if patients do not 
achieve weight loss in the first 16 weeks that continuation of treatment is not beneficial. 
In one 8-week study, orlistat did not appear to have any clinically relevant effect on plasma 
concentrations of a number of psychotropic drugs, including haloperidol, clozapine and 
clomipramine (Hilger et al., 2002). Nevertheless, given that many psychotropic drugs are 
quite lipid soluble, the possibility of alterations in plasma drug concentrations should be 
considered. 
 
Topiramate 
Topiramate is a third generation anticonvulsant introduced to the UK in 1995 and used as a 
first line treatment for focal and generalised seizures. Its anticonvulsant mechanism of action 
is thought to involve potentiation of GABA, inhibition of glutamate (AMPA) and Na+ and Ca+ 
channel blockade. The principal adverse effects are sedation, dizziness, cognitive effects, 
increased risk of renal lithiasis, paraesthesia and psychosis (reported as a low risk). 
Impairments of cognition have been observed across a number of domains (Thompson et 
al., 2000) and appear to be dose dependent (Loring et al., 2011). In one post-marketing 
surveillance study of people with epilepsy they were the most common reason for 
discontinuation of topiramate (Tatum et al., 2001). Trials of topiramate for reduction of 
obesity in the general population were halted due to the severity of adverse effects. 
Weight loss has been reported in a proportion of people with epilepsy prescribed topiramate. 
A meta-analysis of studies of the effect of topiramate in overweight/obese people in the 
general population suggested a weight loss of 5.34 kg compared to placebo (Kramer et al, 
2011). The proposed mechanism of action is a reduction in visceral fat associated with a 
decrease in plasma leptin concentrations. 
Four double blind, placebo controlled RCTs, ranging from 8 to 12 weeks in length, have 
examined the effect of topiramate on weight and/or BMI, when added to antipsychotic 
treatment (Table 4). Three studies found a statistically significant benefit compared to 
placebo. That of Narula et al. (2010) also reported improvements in favour of topiramate vs. 
placebo in fasting glucose, total cholesterol, LDL-cholesterol and blood pressure. 
 
Table 4: RCTs of effect of topiramate vs. placebo on weight in people with psychosis who 
are prescribed antipsychotic medications 
Trial Drug 
naive 
Antipsychotic Length 
of trial 
n 
(final n) 
Results 
Nickel 
(2005) 
no olanzapine 10 wks 49 (f) 
(43) 
Only n=20 with psychosis. 
Difference in weight between the groups: 
5.6 kg (95% CI -8.5, -3.1; p<0.001) 
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Ko 
(2005) 
no cloz, olanz, 
quet, risp 
12 wks 66 
(53) 
Difference in weight loss between groups: 
100mg vs. placebo: -1.68 kg vs. -0.3 kg (ns) 
200mg vs. placebo: -5.35 kg vs. -0.3 kg 
(F = 5.52; p=0.008) 
Afshar 
(2009) 
no clozapine 8 wks 32 
(? 32) 
Change in BMI (kg/m2): 
Topiramate: 24.1 to 23.2 (ns) 
Placebo: 25.2 to 25.4 (ns) 
Narula 
(2010) 
yes olanzapine 12 wks 72 
(67) 
Weight change significantly different 
between groups (p=0.05): 
Topiramate: -1.27 kg 
Placebo: +6.03 kg 
 
In addition, there have been a number of individual case reports and some case series 
suggesting beneficial effects on weight of topiramate added to existing antipsychotic 
treatment (e.g. Khazaal et al., 2007; Hahn et al., 2010). A 12-week non-blind, randomised, 
parallel group study (n=60), in which topiramate or placebo were added at the beginning of 
treatment with olanzapine, found attenuation of weight gain in those participants receiving 
topiramate (+2.3 kg) versus those receiving placebo (+4.1 kg) (Kim et al., 2006). In general, 
the starting dose used for topiramate has been around 25 mg BD with titration up to a final 
maximum dose of between 100 mg to 300 mg per day. Studies in which clinical symptom 
change was the primary outcome measure have tended to titrate up to maximum doses at 
the higher end of this range. 
A further study examined longer term effects (Liang et al., 2014). Ten people with 
schizophrenia were commenced on topiramate for 4 months with a mean weight loss of 1.79 
kg. Topiramate was then discontinued with further mean weight loss up to 4.32 kg reported 
at 12 months after discontinuation. 
One meta-analysis (Mahmood et al., 2013), which included studies of people with 
schizophrenia but also autism and bipolar disorder, as well as studies where weight change 
was not the primary outcome measure, concluded that augmentation of antipsychotic 
treatment with topiramate can prevent or reduce weight gain compared to control treatments, 
with a weighted mean difference of -2.83 kg (95% CI -4.62 to -1.03). 
There has been some evidence for improvement in symptoms of schizophrenia (principally 
items from the General Psychopathology sub-scale of the PANSS) from small, short term 
trials of topiramate, added to existing antipsychotics, in people whose symptoms are 
relatively treatment resistant (e.g. Tiihonen et al., 2005; Hahn et al., 2010). Migliardi and 
colleagues (2007) did not find any effect of topiramate on the plasma concentration of a 
number of antipsychotic drugs. 
 
Reboxetine 
Reboxetine was the first selective noradrenaline reuptake inhibitor to be introduced for the 
treatment of depression and was approved for use in the UK in 1997. It binds to the 
noradrenaline transporter and potently inhibits reuptake of extracellular noradrenaline. There 
are very weak effects at histamine H1 and serotonin 5HT2A receptors and a very weak effect 
on serotonin reuptake. 
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There have been two studies examining the effect of reboxetine alone (Poyurovsky et al., 
2003; Poyurovsky et al., 2007) and one study of a combination of reboxetine and betahistine 
(Poyurovsky et al., 2013) on olanzapine-related weight gain in people with schizophrenia. 
These studies are all from the same research group. They all suggest a significant 
attenuation of rise in BMI and weight gain by reboxetine as well as improvements in some 
related biochemical metabolic measures (triglyceride and leptin) but not others (glucose, 
HDL, LDL, insulin). Meta-analysis of these data shows a weighted mean difference between 
reboxetine and placebo of -1.90 kg (95% CI -3.07 to -0.72) (Mizuno et al., 2014). 
Studies examining the effect of reboxetine on the clinical symptoms of schizophrenia find no 
significant effect on either positive or negative symptoms though improvement in mood has 
been reported in one. A study of its effects on plasma concentrations of clozapine and 
risperidone and their active metabolites did not find any interaction (Spina et al., 2001). 
 
Zonisamide 
Zonisamide is a sulfonamide anticonvulsant unrelated to other anticonvulsants. It was 
approved for use as an adjunctive therapy in adults with certain types of epilepsy in 2005 
and has also been used ‘off label’ in bipolar disorder. It has been found to cause weight loss 
in overweight people with epilepsy (Wellmer et al., 2009) and in a one-year, double-blind, 
placebo controlled RCT was shown to reduce weight in obese adults (Gadde et al., 2012). It 
has been shown to decrease weight in a small case series (n=3) of people with 
schizophrenia (Yang et al., 2010) and also in an open-label study, of rather complex design, 
of various medications, including zonisamide, added sequentially to olanzapine (Hoffmann et 
al., 2012). 
Ghanizadeh and colleagues (2013) conducted a 10-week double-blind, placebo controlled 
RCT in 41 people with schizophrenia who were on a stable dose of their current 
antipsychotic agent, most commonly risperidone (n=23). BMI increased by 2.2 kg/m2 in the 
placebo group and decreased by 0.3 kg/m2 in the zonisamide group (p<0.0001) with parallel 
changes in weight (+1.9 kg vs. -1.1 kg; p<0.0001) and waist circumference. Frequencies of 
adverse effects were reported as no different between the groups, though there were two 
dropouts from the zonisamide group. 
 
Treatments with evidence in general population studies but not in antipsychotic 
treated patients (Group B) 
There are treatments with evidence for efficacy in inducing weight loss in the general 
population but which have no clinical trial data in patients with antipsychotic related weight 
gain (Group B). Lorcaserin is a selective 5HT2C receptor agonist, available in the USA since 
2012 for the treatment of obesity in adults with BMI ≥30 kg/m2 or those with BMI >27 kg/m2 
in the presence of one related comorbidity. A phenteramine and topiramate combination 
(Qsymia®) has also been available in the USA since 2012 for the same indication. At the 
time of writing there were no trials of these two medications for antipsychotic related weight 
gain and these medications were not approved for use in the UK. 
The glucagon-like peptide-1 (GLP-1) receptor agonists are an injectable class of drugs that 
have been approved for the treatment of type 2 diabetes since 2006. They are based on 
analogues of human GLP-1 (liraglutide, albiglutide, dualaglutide) or exendin (exenatide, 
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lixisenatide), which has 53% homology to human GLP-1. Their use is associated with 
significant weight loss and this has led to clinical trials of their use in people with overweight 
or obesity, albeit at higher doses than are used to treat diabetes. Liraglutide has recently 
been approved for the treatment of obesity in the USA and Europe. 
Studies of liraglutide have not been performed in people with psychosis. However, in 
laboratory animal studies, liraglutide has been shown to reverse olanzapine-induced weight 
gain (e.g. Lykkegaard et al., 2008) and in a case report appears to have assisted weight loss 
in an obese female patient with schizophrenia (Ishoy et al., 2013). A clinical trial of exenatide 
for olanzapine-induced weight gain is in progress in the USA. 
Bariatric surgery has not yet been subject to any formal clinical trial in people with psychosis. 
However, there are reports of a number of case series, extracted retrospectively from 
cohorts of all cases subject to bariatric surgery in particular surgical centres (e.g. Hamoui et 
al., 2004; Shelby et al., 2015; Fuchs et al., 2016). The numbers of people with a diagnosis of 
schizophrenia reported within individual case series are usually <10, and make up much less 
than 1% of all bariatric surgical cases. Most of these case series also report people with a 
diagnosis of bipolar disorder, for whom this appears to be performed more commonly. 
However, comparisons, and calculation of a mean percentage across centres, are not 
possible due to variations in how some of the data are collected. People referred for bariatric 
surgery in these centres generally have BMI >40 kg/m2 and many have BMI >50 kg/m2. 
The general conclusion from such reports is that people with diagnoses of schizophrenia and 
bipolar disorder demonstrate the same post-surgical weight loss as others. Improvement is 
generally reported as percentage of excess weight loss (%EWL; i.e. % weight loss above 
ideal weight if BMI was 25 kg/m2). For example, at six months Hamoui et al. (2004) found 
EWL was 39.5% (range 29.4% to 62.9%) in the schizophrenia group versus 46.9% (range 
30.0% to 95.5%) in the control group (no statistically significant difference). Some reports 
describe deteriorations in mental state post-surgery in a proportion of people with psychosis, 
while others find little change. One matched cohort, follow-up study over two years, in 
people with bipolar disorder (n=144), did not find any difference in hospital admissions or 
utilisation of outpatient services in those who underwent surgery compared to those who did 
not (Ahmed et al., 2013). 
Without an appropriate clinical trial, we cannot be certain that bariatric surgery will have the 
same persistence of effect for antipsychotic weight gain as for other forms of obesity as 
mechanisms other than excessive food intake may be involved. Those referred for such 
intervention require to be able to co-operate with post-surgical follow-up, e.g. possible 
dietary changes for micronutrient deficiencies (Moore et al., 2016). It is also unknown, and 
probably unpredictable for individual cases, whether absorption of antipsychotic medications 
will be affected. However, it may sometimes be appropriate to consider bariatric surgery 
within the requirements of NICE guidelines for the management of obesity. 
 
Other treatments with trials in antipsychotic treated patients (Groups C and D) 
There are a small number of other medications, with possible theoretical rationales for use in 
antipsychotic related weight gain, that have been subject to clinical trials. We have 
summarised the data regarding these medications below, but have not reviewed all of these 
in detail. For most of these medications there is either very little data available and/or many 
are not currently available for use. Further information about these medications can be found 
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in a number of systematic reviews and meta-analyses (Maayan et al., 2010; Das et al., 2012; 
Mizuno et al., 2014). 
Six medications that are available for prescription in the UK have been studied (Table 3, 
Group C). Atomoxetine and dextroamphetamine have each been subject to a single negative 
clinical trial in people on antipsychotic medications. Two SSRI antidepressants, fluoxetine 
(two trials) and fluvoxamine (one trial), were found to be ineffective, suggesting that this 
class of drugs is not useful for antipsychotic-related weight gain. Famotidine (one trial) and 
nizatidine (five trials) are both histamine H2 receptor antagonists and inhibit secretion of 
gastric acid. Trials of these were all negative suggesting that this class of drugs is also not 
useful. 
Finally, there have been five other drugs considered for this indication before withdrawal of 
their approval for use in the UK (Table 3, Group D). D-fenfluramine was an anorectic drug 
with a number of effects on the serotonin system. A double-blind, placebo controlled RCT 
(n=29) demonstrated greater weight loss in the D-fenfluramine group (Goodall et al., 1988). 
However, other clinical reports examining its effect on the core symptoms of schizophrenia 
varied as to whether or not these could be worsened. The drug was withdrawn from use in 
1997 due to risks of valvular heart disease. Phenylpropanolamine was an ingredient used in 
many over-the-counter and prescription cough and cold medications as a decongestant but 
also, in some countries, as an anorectic. It was ineffective for antipsychotic related weight 
gain in a single trial, but has been withdrawn from use due to evidence of increased risks of 
haemorrhagic stroke. 
Rosiglitazone was introduced to the UK in 1999 as an antidiabetes drug and withdrawn in 
2010 due to increased risk of myocardial infarction. Two studies in people with schizophrenia 
failed to find benefit for amelioration of weight gain. Clinical trials of sibutramine resulted in 
both positive and negative findings for antipsychotic-related weight gain but in 2010 the drug 
was withdrawn from the UK due to cardiovascular risks. Rimonabant is an inverse agonist 
for the CB1 cannabinoid receptor and reduces appetite. It was introduced in the European 
Union in 2006 for the management of obesity but withdrawn in 2008 due to increases in 
suicidality and depression. A 16-week double-blind RCT in Maryland in people with 
schizophrenia, and BMI >27 kg/m2, was terminated early (because the drug was withdrawn 
from the European market) but data from 15 patients (7 on rimonabant, 8 on placebo) did not 
demonstrate any significant weight loss (Kelly et al., 2011). 
 
Summary (for Groups A – D) 
On the basis of currently available evidence, the treatments summarised here cannot be 
recommended in routine clinical practice. For some there may be exceptional circumstances 
where their use might be considered. 
Only topiramate has a modest amount of evidence from RCTs to suggest it may help to 
mitigate weight gain with potential to induce weight loss. The weighted mean difference from 
one meta-analysis was 2.8 kg. However, the degree of difference between topiramate and 
placebo varies considerably between studies. This seems to be without significant risk of 
adverse effects on core symptoms of psychosis. The evidence base is limited and the 
adverse effects, particularly on cognition, would appear to outweigh any potential benefit for 
most people. 
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Zonisamide, another anticonvulsant, has thus far been tested in only a single RCT but 
appears worthy of further research for this indication. While three studies from one research 
group support the use of reboxetine there is no replication from other research groups and 
the effect seems only to be attenuation of weight gain rather than weight loss. 
The evidence base in favour of amantadine and melatonin is small and is insufficient to 
recommend these treatments for serious consideration. The effect of orlistat is limited to men 
but extremely poor tolerance of steatorrhoea is a huge limiting factor. In practice only a very 
small proportion of people will continue orlistat in the long term making it of little value on a 
routine basis. There may be a role for bariatric surgery in extreme cases though the long-
term benefit of this for antipsychotic induced weight gain requires further evaluation. 
More recent medications, such as lorcaserin and liraglutide, which seem to be effective in 
the general population, may have a role in the future but are yet to be evaluated for 
antipsychotic-induced weight gain. 
 
Interventions for tobacco smoking 
In general, smoking cessation rates for people with schizophrenia are around 50% of those 
for the general population (Williams and Foulds, 2007). Nicotine replacement therapy (NRT) 
is the most widely used treatment but there are no double-blind, placebo controlled RCTs of 
its use in schizophrenia. Seven studies (summarised by Tidey and Miller, 2015) report 
abstinence rates between 9% and 23% at periods varying from 6 months to 12 months. 
These studies were all open-label as far as NRT was concerned but most provided some 
form of individual or group support in addition, which was allocated at random. In general, 
addition of such support improved abstinence rates. One study reported a six-month period 
of single-blind, randomised allocation of nicotine patches versus placebo patches for 
maintenance of smoking cessation (achieved during an earlier open label NRT phase) in 17 
individuals with schizophrenia (Horst et al., 2005). All eight of those receiving active patches 
remained tobacco-free but only three of nine receiving placebo patches (p=0.009). 
It is important to remember that a number of chemicals in cigarette smoke (not nicotine) 
induce the activity of cytochrome P450 1A2 and hence may reduce the plasma 
concentration of a number of psychotropic medications, particularly clozapine but also 
olanzapine, haloperidol and some antidepressants. Thus, it is ideal if smoking is reduced in 
a controlled fashion with monitoring of plasma clozapine levels as necessary and monitoring 
of indications of rising plasma drug levels (such as increased adverse effects) for all 
medications. 
The use of e-cigarettes in the general population, for substitution or smoking cessation, is 
increasing. However, there are concerns about their use in adolescents and whether or not 
e-cigarettes may encourage some people to start smoking. To date there is only one 
uncontrolled study of these for in-patients with schizophrenia in Italy (Minutolo et al., 2013). 
Over 52 weeks 50% of 14 participants demonstrated at least a 50% reduction in the number 
of cigarettes per day smoked, without evidence of deterioration in core symptoms of 
psychosis. 
Studies with buproprion, which attenuates withdrawal symptoms and nicotine reinforcement, 
find that buproprion assists initial smoking cessation but that relapse rates are high following 
discontinuation of buproprion. Individual results for the six RCTs of buproprion, alone or 
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combined with NRT, found either no significant difference from placebo at the end of the 
initial treatment phase or no significant difference at the end of a 3 to 6-month follow-up 
period (Tidey and Miller, 2015). However, many of these studies have small numbers of 
participants. Meta-analysis suggests a significant effect of buproprion at follow up. 
Studies of varenicline (3 RCTs; see Tidey and Miller, 2015) report improved abstinence 
following an initial treatment phase but only one of two reporting abstinence rates after 6 
months or longer found a statistically significant effect. However, again a meta-analysis 
suggests that varenicline has a significant effect. 
Bennett et al. (2013) reviewed 11 studies which investigated psychosocial/behavioural 
approaches in people with schizophrenia and concluded there were reasonable short-term 
abstinence rates but data was too variable to determine clear long-term effects. A recently 
reported UK pilot RCT of a bespoke smoking cessation programme for people with 
psychosis (SCIMITAR), compared to usual care, suggested that the bespoke programme 
resulted in greater effectiveness (Gilbody et al., 2015) This is being followed up by a full trial. 
No RCT data is available with regard to promotion of exercise for smoking cessation. 
Thus, while NRT remains the treatment of initial choice there are no double-blind, placebo 
controlled RCTs to support this. NRT is usually prescribed as part of an overall smoking 
cessation programme and evidence suggests improved outcomes if such other forms of 
support are provided. Meta-analysis of a modest number of studies of buproprion suggests 
some benefit. Evidence to support behavioural/psychosocial approaches on their own and 
varenicline remains limited. There have been concerns that both buproprion and varenicline 
may cause adverse psychological effects (including suicidal ideation), but the evidence is 
conflicting (Hartmann-Boyce and Aveyard, 2016). 
 
Interventions for alcohol misuse 
Despite how commonly alcohol misuse occurs in schizophrenia, there are limited empirical 
data to guide clinicians in managing this usually challenging situation (see Lingford-Hughes 
et al., 2012). A Cochrane systematic review of psychosocial interventions in comorbid 
schizophrenia and substance use disorder revealed that none of these interventions showed 
particular superiority over ‘treatment as usual’ in reducing substance use, retention in 
treatment or improvement in mental state in people with serious mental illnesses (Hunt et al., 
2013). For alcohol misuse, one small RCT of motivational interviewing showed some 
promise (Hunt et al., 2013). Other studies have primarily focused on illicit drugs such as 
cannabis with no, or limited, data relating to alcohol. 
One question is whether a particular antipsychotic medication is preferable in comorbidity? 
Evidence from older studies suggested that first generation antipsychotics did not reduce 
harmful substance use, abuse or dependence, and in fact might increase it (Siris et al., 
1990). Subsequently studies of second generation antipsychotics are primarily retrospective 
surveys, open trials or case series, with very few prospective RCTs. In these studies, there 
is no robust evidence that any particular second generation antipsychotic is associated with 
improvements in alcohol misuse though the uncontrolled studies generally report some 
benefit (see Lingford-Hughes et al., 2012 for further details). The second generation drugs 
studied include olanzapine, risperidone and quetiapine. There have been several case 
reports and surveys suggesting clozapine results in improved substance misuse though no 
prospective or controlled trials. Open studies of flupenthixol and risperidone depot/long-
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acting injections have also reported improvements and a recent one suggested that 
risperidone long-acting injection may be a better choice than oral (Lingford-Hughes et al., 
2012; Green AI et al., 2015). 
With regard to alcohol relapse prevention medication, there is again limited evidence on 
which to develop clinical guidance. For the non-comorbid alcohol dependent populations, 
NICE recommends that acamprosate or naltrexone be offered to all those with moderate to 
severe dependence, with disulfiram as second line (NICE CG115, 2011: section 1.3.5). 
Acamprosate and naltrexone have been used safely in patients with schizophrenia and no 
particular considerations are required (Lingford-Hughes et al., 2012). 
However, psychosis is listed as a contraindication for disulfiram and due to its propensity to 
increase psychosis, through blockade of dopamine-beta-hydroxylase, as well as risks when 
combined with alcohol, its use in schizophrenia is limited. However, there is a trial of 
disulfiram in psychotic patients (73% with bipolar disorder) demonstrating improved drinking 
outcomes, without adverse consequences (Petrakis et al., 2006). This trial also 
demonstrated that use of naltrexone resulted in improved drinking outcomes. There are no 
studies of nalmefene, baclofen or topiramate for alcohol misuse in people with 
schizophrenia. For those with alcohol abuse, there is no robust evidence to support the use 
of such medication to improve drinking behaviours. 
In summary, there is no evidence to support any specific form of psychosocial intervention 
over usual management. While optimisation of antipsychotic treatment is always important, 
there is no RCT evidence that any specific antipsychotic will be more or less beneficial with 
regard to alcohol misuse but there is some preliminary evidence to suggest that clozapine 
may reduce levels of substance misuse in general. Acamprosate and naltrexone may be 
considered as per existing NICE guidelines. 
 
 
MANAGEMENT OF THE INCREASED RISKS FOR DIABETES AND CVD 
 
How should we apply NICE guidelines on pre-diabetes and diabetes in those 
with schizophrenia? 
Decisions regarding management of impaired fasting glycaemia or impaired glucose 
tolerance or regarding the management of diabetes for any individual should be made by 
that person’s general practitioner, or by a consultant physician, in consultation with the 
individual. Initial risk assessment and investigation may be by the mental health team or 
general practitioner. 
 
“Pre-diabetes” 
The identification of a person’s degree of risk for developing diabetes is an important step in 
determining the level of preventative measures required. The current NICE Public Health 
guidance ‘Preventing type 2 diabetes: risk identification and interventions for individuals at 
high risk’ (NICE PH38, 2012) provides detail of how to approach this. The associated 
flowchart provides a summary of the main points: available on-line at 
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http://www.nice.org.uk/guidance/ph38/chapter/1-Recommendations#recommendation-1-risk-
assessment or page 12 of NICE PH38. 
Stage 1 of the NICE diabetes risk identification process recommends that clinicians and their 
patients should be encouraged to make use of validated questionnaires or web based risk 
tools to assess the level of risk for an individual (e.g. http://riskscore.diabetes.org.uk/results 
on the Diabetes UK website). The precise approach, and subsequent advice, depend on age 
and whether the person falls into a ‘high risk group’ - determined by ethnicity, family history 
and whether or not the person has a condition that increases the risk of type 2 diabetes. 
People with psychosis and on antipsychotic medications should be regarded as being in a 
‘high risk group’. In the context of weight gain related to initiation of antipsychotic medication 
it is worth noting that, in the general population, for every 1 kg/m2 increase in BMI the risk of 
developing new-onset type 2 diabetes increases by 8.4%. 
NICE recommends that a blood test should be offered to individuals in the general 
population with a high risk assessment tool score and those who are in a ‘high risk group’. 
This will include people with psychosis, to whom a blood test should be offered at least once 
annually and more often if weight is increasing or symptoms of possible diabetes develop 
(polyuria, nocturia, polydipsia, tiredness, visual disturbance and candida infection). This can 
be a fasting plasma glucose (FPG) or HbA1c, the latter now being regarded as an 
appropriate alternative to FPG by the World Health Organisation. 
While different levels of advice about exercise and diet are provided for those with different 
levels of risk, in reality all people with psychosis should be advised to take broad 
preventative measures such as: at least 150 minutes of moderate intensity physical activity 
per week; maintain their BMI within the healthy range; reduce dietary fat and increase 
consumption of wholegrains, vegetables and fruit, while minimising intake of highly calorie 
dense foods. This would be consistent with the NICE guideline on schizophrenia (NICE 
CG178, 2014). 
 
In Stage 2 of the NICE diabetes risk identification process (NICE PH38), three levels of risk 
are described, with associated recommended management: 
1. Moderate risk: FPG< 5.5mmol/l or HbA1c <42 mmol/mol 
 Discuss the risk of developing diabetes 
 Help modify individual risk factors 
 Offer tailored support services 
 
2. High risk: FPG 5.5–6.9 mmol/l or HbA1c 42–47 mmol/mol 
 Offer an intensive lifestyle change programme to increase physical activity 
 Achieve and maintain weight loss 
 Increase dietary fibre and reduce fat intake 
 
3. Possible type 2 diabetes: FPG ≥7.0 mmol/l or HbA1c ≥48 mmol/mol 
 If asymptomatic carry out a further blood test to confirm or reject the presence 
of diabetes 
NICE PH38 suggests that individuals who are at high risk of developing diabetes and whose 
blood glucose shows they are still progressing towards type 2 diabetes, despite their 
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participation in an intensive lifestyle-change programme, or those who are unable to 
participate in an intensive lifestyle-change programme, should be considered for treatment 
with metformin. Background literature relating to the use of metformin to reduce the risk of 
progression to diabetes and to reduce weight gain has been discussed in an earlier section 
and will not be repeated here. 
 
Diabetes 
People with a psychotic illness who develop diabetes should receive the same standard of 
diabetes care as the rest of the general population. It is important to remember that all 
people require an individualised approach and should be encouraged to engage with the 
appropriate local diabetes services. For example: someone with persecutory delusions may 
find it more difficult to attend a public gym for an appropriate exercise programme or go to a 
public swimming pool. 
The advice in previous sections, above, regarding management of weight gain should be 
revisited if an individual goes on to develop diabetes secondary to overweight or presents 
with diabetes after a period of non-engagement with services. Ideally medications that may 
contribute to weight gain should be avoided but this is often very difficult or impossible in the 
case of antipsychotic treatment. 
An updated version of the NICE clinical guideline on the management of type 2 diabetes was 
published in December 2015: ‘type 2 diabetes in adults: management’ (NICE NG28, 2015) 
provides guidance on management and is reflected in the NICE pathway for diabetes 
available on-line (Pathway available at: http://pathways.nice.org.uk/pathways/diabetes. PDF 
available at: http://www.nice.org.uk/guidance/ng28/resources/algorithm-for-blood-glucose-
lowering-therapy-in-adults-with-type-2-diabetes-2185604173). Key points for the 
management of type 2 diabetes, from NICE NG28, which will be the most common 
presentation in the context of antipsychotic treatment, are: 
1. Education about diabetes, dietary advice and lifestyle programmes should be offered, 
especially if the person is overweight. This should continue at regular intervals 
following diagnosis. 
2. The target for HbA1c should normally be 48 mmol/mol (6.5% in old units) with the 
precise target being dependent on the clinical situation and agreement with the 
person. 
3. HbA1c should be monitored 3-6 monthly until stable on unchanging therapy. 
Thereafter monitoring should be every 6 months. 
4. If, despite lifestyle interventions, HbA1c remains ≥48 mmol/mol (6.5%) then drug 
therapy should be offered. 
5. Initial Drug Treatment: Standard-release metformin should be the first line medication 
but the dose must be reviewed if eGFR is <45 ml/minute/1.73 m2 and should be 
stopped if eGFR is <30 ml/minute/1.73 m2. 
6. If metformin is contraindicated or not tolerated consider initial drug treatment with: a 
dipeptidyl peptidase-4 (DPP-4) inhibitor, or pioglitazone, or a sulfonylurea. 
7. First Intensification of Drug Treatment (if HbA1c rises to 58 mmol/mol; 7.5%) 
(a) If initial drug treatment with metformin has not continued to control HbA1c to below 
the person’s individually agreed threshold for intensification, consider dual therapy 
with: metformin and a DPP-4 inhibitor, or metformin and pioglitazone, or metformin 
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and a sulfonylurea. (In occasional situations metformin and an SGLT-2 inhibitor may 
be appropriate.) 
(b) If metformin is contraindicated or not tolerated and initial drug treatment has not 
continued to control HbA1c to below the person’s individually agreed threshold for 
intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone, or a 
DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea. 
(c) For any of the above regimens, support the person to aim for an HbA1c level of 53 
mmol/mol (7.0%). 
8. Second Intensification of Drug Treatment (if HbA1c rises to 58 mmol/mol) 
(a) In adults with type 2 diabetes, if dual therapy with metformin and another oral 
drug has not continued to control HbA1c to below the person’s individually agreed 
threshold for intensification, consider either: triple therapy (metformin, a DPP-4 
inhibitor and a sulfonylurea; or metformin, pioglitazone and a sulfonylurea); or 
starting insulin-based treatment. 
(b) If triple therapy with metformin and two other oral drugs is not effective, tolerated 
or contraindicated, consider combination therapy with metformin, a sulfonylurea and 
a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: 
 have a BMI of 35 kg/m2 or higher (adjust accordingly for people from black, 
Asian and other minority ethnic groups) and specific psychological or other 
medical problems associated with obesity; or 
 have a BMI lower than 35 kg/m2 and for whom insulin therapy would have 
significant occupational implications, or weight loss would benefit other 
significant obesity-related comorbidities. 
9. Failure of these regimens will, in most cases, lead to insulin-based treatment. 
(Note: the above is a summary of key points. The revised guideline itself should be 
consulted for details regarding recommendations for specific clinical situations.) 
 
There are many potentially serious consequences of diabetes. The appropriate monitoring 
for these is described in NICE NG28 (2015). Given the high mortality from cardiovascular 
disease among those with schizophrenia issues relating to this are expanded upon below. 
 
Reducing cardiovascular risk in severe mental illness 
Data from the Framingham Heart Study have identified a number of factors as useful in the 
prediction of future cardiovascular disease (CVD), including: BMI > 27kg/m2, smoking, 
elevated total cholesterol, presence of diabetes and presence of hypertension. A number of 
predictive models have been developed and refined, each using similar, but sometimes 
slightly different, variables. However, it is clear that variables such as those above have 
additive effects and that the total risk is greater than the sum of the individual risk factors 
(Wilson et al, 1998). 
A 10-year follow-up study of 1,307 individuals (mean age 56 years) on General Practice 
Severe Mental Illness registers in Cheshire (UK) demonstrated the progression over time 
with respect to some of these problems (Heald et al., 2016). Mean baseline BMI increased 
from 28.6 kg/m2 to 31.0 kg/m2 (p=0.0002). The number known to have type 2 diabetes 
increased from 26 (1.9%) at baseline to 101 (7.7%) at the end of the follow-up. Over the 
period of the study there was increasing prescription of statins. At baseline 33 (2.5%) were 
46 
 
on antihypertensive medication and by the end of follow-up a further 162 (12.4%) patients 
had been commenced on antihypertensive medication. These data suggest that progression 
may occur in BMI and the development of diabetes and hypertension within a relatively older 
population of individuals with psychosis, though the study is limited by not having a control 
group to account for overall population trends. 
The results of the second round of the National Audit of Schizophrenia (Royal College of 
Psychiatrists, 2014) show that not all service users are adequately monitored for these 
problems and that even when problems are identified these are not always treated. For 
example, for diabetes, in Mental Health Trust case records, only 57% had a measure of 
glucose control in the previous 12 months and of those with evidence of abnormality only 
36% had evidence of receiving intervention. Thus it is vital that clinicians, service users and 
carers maintain an active approach to regular assessment of appropriate risk factors for 
cardiovascular disease: smoking, BMI, glucose control, lipid profile, blood pressure and 
family history of premature CVD (<55 years of age in men and <65 years in women). 
A useful resource to support clinical decision making in relation to the above risk factors is 
the Lester UK adaptation of the ‘Positive Cardiometabolic Health Resource’ (Shiers et al., 
2014), which was developed from the original Australian version (Curtis et al., 2012). This 
provides staff in mental health teams with a simple outline of which clinical measures should 
be monitored, what the appropriate values are for each measure and what interventions 
should be considered if these measures are outside appropriate limits. (This resource is 
available through the Royal College of Psychiatrist’s website: 
http://www.rcpsych.ac.uk/workinpsychiatry/qualityimprovement/nationalclinicalaudits/national
schizophreniaaudit/nasresources.aspx). (Note: The monitoring and interventions suggested 
in the ‘Positive Cardiometabolic Health Resource’ are very similar to those suggested for the 
NHS Health Check [Public Health England, 2016]. This is a 5-yearly review expected to be 
carried out for all eligible people between the ages of 40-74 years in the general population.) 
The management of weight gain and abnormal glucose control, smoking and alcohol misuse 
have been described earlier. Promotion of exercise, to improve cardiovascular fitness, is 
appropriate and may be through the mental health team or local primary care services 
depending on local arrangements. Exercise may improve cardiovascular fitness even in the 
absence of weight loss. Service users with hypertension should be referred to their general 
practitioner for further investigation and management. Note that antipsychotic medications 
may enhance the hypotensive effect of the commonly prescribed antihypertensive 
medications. 
Service users with dyslipidaemia should be referred to their general practitioner. 
Management will usually be as per current guidelines such as the NICE guideline on Lipid 
Modification (NICE CG181, 2014) or the JBS2 Joint British Societies’ Guidelines on 
Prevention of Cardiovascular Disease in Clinical Practice (British Cardiac Society et al., 
2005). All people with dyslipidaemia should receive advice about diet, exercise, weight 
management and smoking cessation. Those with total cholesterol concentration of >9.0 
mmol/l or a non-HDL cholesterol concentration of >7.5 mmol/l or triglyceride concentration of 
>10 mmol/l should be referred for specialist advice. 
Regarding the prescription of statins, NICE guidance is that if lifestyle advice is ineffective in 
normalising the lipid profile then a statin should be considered after screening for their risk of 
CVD, usually with QRISK2 in the UK. (Note that risk assessment may be different in certain 
circumstances, e.g. people with type 1 diabetes, those with familial hypercholesterolaemia 
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and other situations outlined in NICE CG181.) Initially offer atorvastatin for the primary 
prevention of CVD to people who have a 10% or greater 10-year risk of developing CVD. 
Statins should also be offered for the primary prevention of CVD to people with type 2 
diabetes who have a 10% or greater 10-year risk of developing CVD. Generally, people in 
these categories will be over 40 years of age. 
For people with diabetes aged 18 to 39 years who have one of: diabetic complications; poor 
blood glucose control; hypertension; features of the metabolic syndrome; or family history of 
premature CVD in a first degree relative (at least one of which may often be present in a 
service user with psychosis), then the JBS2 guidelines suggest commencing a statin though 
the NICE guideline does not. The cost effectiveness and safety of prescribing statins before 
the age of 40 years is not clear, particularly for women of childbearing age. 
Prescription of a statin requires monitoring, including monitoring of hepatic transaminase 
enzymes at baseline, 3 months and 12 months, but not thereafter unless clinically indicated. 
Statins are contraindicated in pregnancy and ideally should be stopped 3 months before 
conception. 
 
Wider considerations in Primary Care and Secondary Care 
The Government report ‘No Health Without Mental Health: A Cross-Government Mental 
Health Outcomes Strategy for People of All Ages’ (Department of Health, 2011) gave a 
commitment to improve physical health outcomes for those with mental illness as well as a 
more general commitment to improve access to mental health services. The NICE clinical 
guidelines referred to in earlier sections of this document provide guidance regarding the 
management of certain specific physical health problems relevant to issues surrounding 
obesity, diabetes and cardiovascular disease in people with psychosis, including those 
receiving antipsychotic medications. 
Informal feedback from Trusts involved in relevant national audit programmes indicates that 
in many Mental Health Trusts the physical resources necessary for doing this are often 
lacking. This and the poor performance of many Trusts on aspects of monitoring physical 
health, in both the first and second rounds of the National Audit of Schizophrenia (Royal 
College of Psychiatrists, 2012 and 2014; Crawford et al., 2014; Patel et al., 2014), has led to 
the introduction of relevant indicators as part of the national Commissioning for Quality and 
Innovation (CQUIN) programme (NHS England, 2015; indicators 4a and 4b), which 
incentivises NHS Trusts to ensure that such care is provided. These cover aspects of the 
physical health care of people with psychotic illness in all types of inpatient units and those 
under the care of community based early intervention psychosis services. 
In primary care the Quality Outcomes Framework (QOF) provides voluntary incentives, 
through the General Medical Services (GMS) contract, to improve care in certain specific 
domains. The guidance for the GMS contract prior to 2015 provided specific indicators in the 
Clinical Domain related to physical health in this population. These were for maintaining an 
annual record of: blood pressure (MH003), cholesterol/HDL ratio (MH004), blood glucose or 
HbA1c (MH005), BMI (MH006) and alcohol consumption (MH007). Two further indicators in 
the Public Health Domain related to smoking (SMOK 002 & SMOK 005). Other indicators for 
diabetes, primary prevention of cardiovascular disease and obesity in the general population 
were expected to be inclusive of service users with mental health problems. 
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However, for the periods 2014 to 2015 and 2015 to 2016 the QOF indicators were amended, 
removing the Clinical Domain indicators relating to monitoring of cholesterol/HDL ratio, blood 
glucose/HbA1c and BMI. Additional statements relating to these were added, as below, but 
without financial incentive: 
 It is recommended that patients receive health promotion and prevention advice 
appropriate to their age, gender and health status. 
 The NICE clinical guideline on schizophrenia recommends the components of a 
review and has separated them out to create a series of indicators. The NICE clinical 
guideline on bipolar disorder recommends that patients with bipolar affective disorder 
have a physical health review, normally in primary care, to ensure that the following 
are assessed: 
o lipid levels, including cholesterol in all patients aged 40 or over even if there is 
no other indication of risk 
o plasma glucose levels 
o weight 
o smoking status and alcohol use 
o blood pressure 
 QOF continues to incentivise annual monitoring of blood pressure, alcohol and 
smoking status for patients with schizophrenia, bipolar affective disorder and other 
psychoses. Clinicians should use their professional judgement to decide when and 
how frequently checks of lipid levels, glucose levels and weight should be carried out, 
in accordance with the needs of each patient. 
(Italicising and underlining here and below provided by the authors of this guideline 
document.) 
For the 2016 to 2017 QOF, NICE proposed, to NHS England and the General Practitioner’s 
Committee, restoration of the indicators relating to lipids and glucose, as well as an 
expectation that these are carried out from age 18 years (40 years in the 2013/2014 QOF). 
An amendment to the obesity indicator, in the Public Health Domain, would have required a 
register of all patients aged 18 years and over whose BMI is ≥25 kg/m2 in the previous year, 
rather than the existing BMI ≥30 kg/m2. If implemented, these changes would have returned 
the QOF to a situation where it largely paralleled NICE CG178. Following discussions, 
however, it was reported in February 2016 that it was decided not to make changes to the 
QOF indicators for 2016/17 (http://www.nhsemployers.org/your-workforce/primary-care-
contacts/general-medical-services/quality-and-outcomes-framework/changes-to-qof-2016-
17). The QOF indicators, and associated additional statements, thus remain as per the 
arrangements for 2015/16. 
NICE CG178 (paragraph 1.3.6.5) recommends that: “the secondary care team should 
maintain responsibility for monitoring service users' physical health and the effects of 
antipsychotic medication for at least the first 12 months or until the person's condition has 
stabilised, whichever is longer. Thereafter, the responsibility for this monitoring may be 
transferred to primary care under shared care arrangements”. Thus, particularly for people in 
their first episode of psychosis, it is likely that Trusts will need to provide programmes for the 
monitoring of physical health as significant weight gain commonly occurs in the early months 
of treatment. All members of Mental Health Teams need to ensure they have a proper 
understanding of the issues surrounding weight gain, weight management and 
cardiovascular risk.  
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Paragraph 1.5.3.2 of CG178 recommends that “GPs and other primary healthcare 
professionals should monitor the physical health of people with psychosis or schizophrenia 
when responsibility for monitoring is transferred from secondary care, and then at least 
annually”. This is inconsistent with aspects of the QOF statements italicised and underlined 
above and can lead to conflicting views between primary and secondary care regarding the 
frequency of monitoring in the longer term and whether it should be carried out in primary 
care or by the mental health team. 
The CG178 guideline also places an onus on clinicians in both settings to ensure they are all 
fully aware of the results of assessments of physical health, irrespective of where the 
assessment was carried out. A further complication in this is that epidemiological data 
suggests that 31% of people with severe mental illness have only been seen by primary care 
services during the previous 12 months (Reilly et al., 2012). Within primary care it is also 
clear that it can be difficult to ensure engagement of some people with severe mental illness 
with physical health monitoring arrangements. 
These are issues that require careful local discussions and negotiations between Trusts and 
local general practitioners but are issues which it is essential to resolve to ensure adequate 
care. Probably the best solutions are going to involve joint working and shared care 
between primary care and local mental health teams. One recent example of this is a 
new service model provided across Newham CCG’s area: 
http://www.england.nhs.uk/2015/05/15/mental-health-scheme/. 
There is also the question of how best to provide appropriate lifestyle-change programmes. 
Much of the resource for this type of programme for the general population has been 
transferred, through Public Health England, to local authority budgets, though CCGs will also 
commission such services from local Community Trusts. Evidence suggests that targeted 
services (e.g. for smoking cessation) work best and it is likely that Trusts and local 
authorities will have to work together to provide such services. It is essential that people with 
psychosis, particularly in their first episode of illness, are given access to lifestyle change 
programmes. 
Finally, it is clearly important to prevent an accumulation of physical health risk factors by 
any individual. Weight gain and the development of obesity are important risk factors for 
diabetes and cardiovascular disease in people with schizophrenia. It is thus essential that 
proper arrangements for monitoring weight are in place for all those presenting with a first 
episode of psychosis, that systems are in place to recognise those individuals who are 
gaining weight at an early stage of treatment and that members of mental health teams are 
aware of the options for managing undue weight gain. 
 
 
Acknowledgements 
The participants are indebted to Susan Chandler and Lynne Harmer who organised and 
supported the Expert Group meeting. We thank Professor Chris Hollis, Professor of Child & 
Adolescent Psychiatry, University of Nottingham, for his assistance in the writing of Appendix 
2. The authors would like to thank Dr Jenny Gingles for her assistance with proof reading. 
 
50 
 
Declaration of conflicting interests 
Declarations of interest of the participants are held by the BAP office and are available for 
consultation. There has been no involvement of pharmaceutical companies at any stage of 
the development of these guidelines, from conception to publication. 
 
Funding 
The costs of the Expert Group meeting and any miscellaneous expenses were met from the 
funds of the British Association for Psychopharmacology. 
 
 
APPENDIX 1 
Dyslipidaemia: This term is used frequently throughout the document. The following provides 
a definition of this term and some explanation of related terminology. Dyslipidaemia refers to 
an aberrant blood lipid profile and, in our context, to elevations of potentially harmful lipids 
with reductions of those that may be protective for CVD. Traditionally this was elevation of 
total cholesterol and/or triglycerides, high LDL levels and often low HDL levels. However, it is 
now regarded as more appropriate (NICE CG181, 2014) to measure non-HDL cholesterol 
levels instead of LDL levels. This gives a measure of all of the lipids that may promote 
arterial plaque production: LDL cholesterol level and the levels of VLDL, IDL, and 
chylomicrons. Non-HDL cholesterol is calculated from ‘Total cholesterol minus HDL-
cholesterol’ and has the further advantage of not requiring a fasting blood sample for its 
measurement. Thus, increased risk of CVD is related to high total cholesterol and/or 
triglycerides and high non-HDL cholesterol levels. Some of the studies quoted will refer to 
the traditional measures of lipid biochemistry and some to the more recent measures. We 
have not distinguished between these approaches in reviewing the available clinical trials but 
the use of non-HDL cholesterol applies to current NICE guidance. 
 
 
APPENDIX 2 
Children and young people: The scope for the development of these guidelines was adults 
with psychosis over the age of 18 years. Weight gain, and appropriate interventions for this, 
in children and young people with psychosis is clearly an important topic. One of the reasons 
for excluding this population in our evidence review was the paucity of good data and RCTs 
in relation to interventions for this group, from which evidence based guidelines could be 
written. The purpose of this Appendix is to provide some link between these guidelines and 
parallel issues for younger people. However, it is not intended to be a definitive review of the 
subject. 
A NICE guideline has been published regarding the recognition and management of 
psychosis in children and young people (NICE CG155, 2013). In relation to monitoring for 
weight gain, metabolic and cardiovascular risk factors, this takes a similar approach to that 
adopted in the subsequent NICE guideline for adults with psychosis (NICE CG178, 2014). 
For those individuals who develop significant weight gain CG155 advocates, as we have for 
adults, lifestyle interventions as the first line of approach. Our review of clinical trial data for 
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lifestyle interventions includes studies of people experiencing a first episode of psychosis, 
some of whom are <18 years of age. 
There are no specific recommendations in CG155 regarding which antipsychotic 
medications should or should not be considered for children and young people in their first 
episode of psychosis. However, a recent NICE Evidence Update (NICE Evidence Update 
76, 2015) suggests that, because of the magnitude of the metabolic effects caused by 
olanzapine, olanzapine may not be suitable as a first line medication for young people in 
their first episode of psychosis. 
One review of studies of weight gain and the metabolic risks associated with treatment with 
antipsychotic medications, in children and young people, collated evidence from four types 
of published studies: randomized controlled trials, indirect comparisons of drugs using data 
from individual trials versus placebo, naturalistic cohort studies and pharmacoepidemiologic 
studies (Maayan and Correll, 2011). The majority of these studies included young people 
with other diagnoses as well as schizophrenia. Similar to the findings for adults, the available 
data demonstrate a hierarchy of risk for the development of significant weight gain. The 
order of drugs from high to low risk was essentially the same as for adults: olanzapine ≥ 
clozapine > risperidone ≥ quetiapine > aripiprazole = ziprasidone. This is clearly relevant for 
considerations of initial treatment as well as switching of antipsychotic medication. 
Some authors suggest that weight gain with antipsychotic medications is disproportionately 
greater in young people compared to adults (e.g. Kryzhanovskaya et al., 2012). Others (e.g. 
Correll et al., 2009) have concluded that younger people are not more vulnerable to this than 
adults, and suggest that this may be an apparent effect because many studies of adults 
include people who have previously been prescribed antipsychotics, and are starting from a 
baseline where they have already gained some weight, before being changed to an 
alternative drug. 
However, it is important to remember that the risk of type 2 diabetes in children and young 
people using antipsychotics is increased three-fold, compared with the risk in a matched 
healthy cohort, (Bobo et al., 2013) and that onset of diabetes at an early age is likely to have 
greater long-term consequences. Further, current evidence shows that the decline in β-cell 
function is three to four times faster in young people with type 2 diabetes than in adults and 
that therapeutic failure rates are higher (Hannon and Arslanian, 2015). 
In our guideline, we have recommended two other interventions as worth consideration for 
weight gain in adults with psychosis: adjunctive aripiprazole and adjunctive metformin. There 
are no RCT data available in relation to adjunctive aripiprazole in young people. Maayan and 
Correll (2011) review two double-blind, placebo controlled RCTs of adjunctive metformin in 
young people. One of these demonstrated a statistically significant reduction in weight gain 
but the other did not, making it impossible to make any recommendation. 
Some of the questions that cannot be answered adequately from current data may be 
resolved on the completion of a currently running, six-month, open-label, randomised trial of 
metformin and healthy lifestyle education in antipsychotic treated children and young people 
(age 8 – 19 years), with significant weight gain, in the United States (Reeves et al., 2013). 
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